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Tuberous sclerosis complex (TSC) is a multisystem, autosomal dominant disorder
affecting approximately 1 in 6000 births. Developmental brain abnormalities cause
substantial morbidity and mortality and often lead to neurological disease including
epilepsy, cognitive disabilities, and autism. TSC is caused by inactivating mutations in
either TSC1 or TSC2, whose protein products are known inhibitors of mTORC1, an
important kinase regulating translation and cell growth. Nonetheless, neither the
pathophysiology of the neurological manifestations of TSC nor the extent of mTORC1
involvement in the development of these lesions is known. Murine models would greatly
advance the study of this debilitating disorder. This thesis will describe the generation and
characterization of a novel brain-specific mouse model of TSC, Tsc2flox/ko;hGFAP-Cre. In
this model, the Tsc2 gene has been removed from most neurons and glia of the cortex and
hippocampus by targeted Cre-mediated deletion in radial glial neuroprogenitor cells. The
Tsc2flox/ko;hGFAP-Cre mice fail to thrive beginning postnatal day 8 and die from seizures
around 23 days. Further characterization of these mice demonstrated megalencephaly,
enlarged neurons, abnormal neuronal migration, altered progenitor pools, hypomyelination,
and an astrogliosis. The similarity of these defects to those of TSC patients establishes this
mouse as an excellent model for the study of the neuropathology of TSC and testing novel
therapies. We further describe the use of this mouse model to assess the therapeutic
iv

potential of the macrolide rapamycin, an inhibitor of mTORC1. We demonstrate that
rapamycin administered from postnatal day 10 can extend the life of the mutant animals 5
fold.

Since TSC is a neurodevelopmental disorder, we also assessed in utero and/or

immediate postnatal treatment of the animals with rapamycin. Amazingly, combined in
utero

and

postnatal

rapamycin

effected

a

histologic

rescue

that

was

almost

indistinguishable from control animals, indicating that dysregulation of mTORC1 plays a
large role in TSC neuropathology. In spite of the almost complete histologic rescue,
behavioral studies demonstrated that combined treatment resulted in poorer learning and
memory than postnatal treatment alone. Postnatally-treated animals behaved similarly to
treated controls, suggesting that immediate human treatment in the newborn period might
provide the most opportune developmental timepoint for rapamycin administration.
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Chapter One:
Background and Introduction
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Introduction
In 1879, the pediatrician Désiré-Magloire Bourneville performed an autopsy on a 15year old mentally handicapped girl named L. Marie who had died in a psychiatric hospital:
She had suffered seizures most of her life, at first partial and, after the
age of 2 years, generalized(at the age of 3 years, she suffered
frequent episodes of status epilepticus and developed a right spastic
hemiplegia. (Pathologic examination of the brain disclosed raised,
opaque, and sclerotic areas in some of the cerebral convolutions(
[and] what appeared to be white nodular tumors embedded in the
corpus striatum and protruding into the lateral ventricles.” Bourneville
coined the term tuberous sclerosis of the cerebral convolutions for this
unique potato-like consistency, hence the adjective tuberous. Notably,
Bourneville also found small yellowish white tumors in the kidneys,
protruding 3 to 5 mm over the surface, which he thought were unrelated
to the cerebral pathology. He concluded that Marie’s partial seizures
originated in an extensive sclerotic area, indeed a large tuber((1).

Though similar characteristics had been previously described by other physicians (1), it
was not until Bourneville’s detailed account and naming of this disease that it was brought
from relative obscurity into common medical knowledge. Thanks to his contributions and
that of the many physicians, scientists, and patients who followed, we now have a better
understanding of the intricacies of tuberous sclerosis complex (TSC), including the genetic
etiology and some of the major pathways that are affected. This in turn has allowed for the
creation of cell lines and animal models with which the pathophysiology of the disease
continues to be more clearly elucidated. Though much still remains unknown nearly a
century and a half after Bourneville’s initial report, the TSC field has advanced to the point
that clinical trials targeting the biochemical disease pathways are under way. In the
following chapters, I will discuss the main features of TSC, some of the significant
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advances made within the past ten years, and the contributions of our laboratory to the
growing body of knowledge regarding this disease.

Clinical Features of Tuberous Sclerosis Complex
Tuberous sclerosis complex is an autosomal dominant tumor suppressor disease with
an incidence of approximately 1 in 6000 live births (2). It is characterized by hamartomas,
or benign tumors, which can occur in various organ systems, most notably the skin, heart,
lungs, kidneys, and brain (3). While TSC is a highly penetrant disease, the clinical
manifestations vary greatly from patient to patient and may occur at different developmental
timepoints (4).
Skin lesions, for example, may be detected at all ages and are found in almost 90% of
patients with TSC. These lesions are often found as small growths on the face (facial
angiofibromas), as discolored (hypopigmented macules) or raised areas (shagreen
patches) along the back or extremities, or as thickened growths along the finger or toenails
(ungual fibromas) (5). Aside from seizures, skin lesions are one of the most common
reasons TSC patients come to medical attention (4). Though they are a cosmetic nuisance,
this manifestation of TSC usually has little clinical impact on patients.
Cardiac lesions are detectable in nearly 50-70% of infants with TSC (6). They are
considered one of the less serious aspects of TSC for a majority of those affected, though
they may cause severe problems in a small number of afflicted patients. Cardiac
rhabdomyomas are the most common tumor diagnosed in utero and are useful for prenatal
diagnoses of TSC, though for the most part they spontaneously disappear later in life (7).
However, cardiac rhabdomyomas may cause a number of critical defects in infancy, such
as heart failure or complete heart block (8).
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Pulmonary manifestations of TSC are usually found in early adulthood and specifically
in women, at a rate of 26-39% (9). The sex-specific nature of lymphangioleiomyomatosis
(LAM), characterized by a proliferation of defective smooth muscle growth, has led to
theories regarding the role of estrogen in the formation of these lesions. Though many of
these women are asymptomatic, a study by the Mayo Clinic of 49 TSC-related deaths cited
4 as the result of LAM (10), making it the third most frequent cause of death after kidney
and brain lesions.
The renal manifestations of TSC are pathologically heterogeneous and may occur from
childhood through adulthood. About 55-75% of patients are affected with renal
angiomyolipomas, or benign tumors composed of vascular, fat, and smooth muscle
elements, which are often bilateral. The abnormal vasculature of these tumors makes
spontaneous life-threatening bleeding a serious concern. Presence of epithelial renal
lesions, usually found in the form of cysts, renal cell carcinomas, or polycystic kidney
disease, may also lead to hypertension and renal failure (11).
Though tumor presence in other organs may be devastating, the brain abnormalities of
TSC are the cause of the most severe morbidity and mortality of this disease (12). The
pathophysiology of these brain lesions remains largely unknown, and treatment remains
inadequate. Through the creation, characterization, and treatment of a unique animal
model, my dissertation elucidates some of these pathophysiologic mechanisms.

Neuropathology of Tuberous Sclerosis Complex
Nearly 95% of patients with TSC exhibit some form of brain pathology, which often
leads to a wide range of neurological and behavioral abnormalities such as epilepsy,
cognitive dysfunction, mental retardation, and autism. These features are usually detectable
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in early childhood and are often resistant to existing therapies (13). Although the
classification of TSC as a "prototypical neurodevelopmental disorder (14)” is well accepted
in the field, little is known regarding the development of TSC neuropathology or how it
contributes to brain dysfunction.
The most common brain lesions found in TSC patients are cortical tubers,
subependymal nodules (SENs), and subependymal giant cell astrocytomas (SEGAs) (15).
Cortical tubers are present in over 80% of patients and are likely intimately related to the
neurobehavioral abnormalities found in TSC. Tubers are firm, "potato-like" growths of
variable size that occur most often at the gray-white junction. Histologically they
demonstrate a loss of cortical lamination, where the distinct organization of the six-layer
cortex is disrupted. A proliferation of disordered and dysplastic neuronal and glial cells are
also found in tubers, including "giant cells," or cytomegalic cells of mixed neuronal and
astrocytic lineage (16). Increased tuber burden is strongly predictive of infantile spasms
(17), a characteristic seizure condition of TSC with a typical onset between 4-8 months, in
which the body abruptly bends forward and the arms and legs stiffen (18). This epileptic
syndrome is often associated with poor neurologic prognosis and severe mental
retardation, and occurs in roughly 20-30% of infants with TSC (19). It is unknown whether
neurological dysfunction may be attributed to the presence of tubers alone or as a result of
seizures caused by tuber presence (20).
SENs are small growths that may be partially or completely calcified. They are typically
asymptomatic and line or protrude into the lateral and third ventricles (21). Like tubers, they
are mainly composed of dysplastic astrocytes and mixed-lineage neuronal or astrocytic cell
components. SEGAs, or giant-cell tumors, are thought to derive from SENs and occur in
about 10% of TSC patients. Though they do not become malignant glial tumors, SEGAs
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may enlarge over long periods of time and cause obstruction of cerebrospinal fluid
pathways, hydrocephalus, endocrinopathy, and even death (16).
The development of these brain lesions and what role they play in subsequent brain
dysfunction is not well understood. However, other histologic features of TSC, such as
heterotopic neuronal aggregates and varying degrees of cortical cytoarchitectural
disorganization, suggest that the disease may be thought of more cohesively as a neuronal
migration disorder (22) that is also characterized by aberrant cellular proliferation and
differentiation. Though establishment of the neurodevelopmental nature of the disorder has
greatly assisted studies in determining the best approaches to modeling and studying TSC,
it was not until the discovery of the genetic etiology of the disease that advances in
experimental research could be made.

Genetics of TSC
Several decades passed following Bourneville’s initial account of TSC before some
physicians began noticing a trend in TSC patient families. In 1910, Kirpicznik first
recognized TSC as a genetic condition when he investigated a family consisting of three
generations of affected individuals and described the disease in identical as well as
fraternal twins. Gunther and Penrose noticed in 1935 the dominant inheritance pattern of
the disease and suggested that a high mutation rate was “causal” in TSC (23).
The genes responsible for the disease, TSC1 and TSC2, were eventually identified
using linkage analysis and positional cloning in 1997 and 1993, respectively (24, 25).
TSC1, located on chromosome 9q34, encodes a 23-exon transcript that results in a 130
kDa protein named hamartin. TSC2, identified on chromosome 16p13, is associated with a
200 kDa protein named tuberin and encodes a 41-exon transcript.

6

TSC is caused by inactivating mutations in either TSC1 or TSC2 (26). The prevailing
hypothesis regarding lesion formation states that inactivation of both alleles of either gene,
or loss of heterozygosity (LOH), is required, in accordance with Knudson's two-hit tumor
suppressor gene model (27). Studies showing LOH in lesions including SEGAs but not the
surrounding normal tissue have supported this hypothesis (28-30), and this finding has
been observed in most types of hamartomas found in TSC patients. However, LOH is
observed more consistently in some lesion types than others, with only rare observances in
cortical tubers (31, 32). Recent studies have suggested that loss of tuberin function in
tubers does not primarily occur as the result of a second hit event, but rather as a
consequence of Erk (extracellular signaling-regulated kinase) phosphorylation of tuberin,
which suppresses its biochemical and tumor-suppressor functions (33). This hypothesis is
supported by findings that hyperactivation of Erk is frequently observed in tubers (34-36).
The exact mechanism by which tuber formation occurs is therefore the subject of ongoing
debate.
Though mutations within either gene give rise to TSC pathology, the locations and
types of mutations vary widely. Over 900 unique allelic variants have been reported for both
genes, representing large and small deletions, rearrangements and insertions, nonsense,
missense, and spliced mutations (37-40). Interestingly, the frequency of mutations found in
TSC2 is higher than that of TSC1, such that over 65% of sporadic cases, which represent
66% of all TSC cases reported, are TSC2-based (26). TSC2-based cases also have a
more debilitating form of the disease. It is speculated that this disparity in frequency may be
the result of increased germline and somatic mutations in TSC2 compared to TSC1, though
why TSC2 mutations result in more severe disease is not clearly understood (41). Recent
studies have suggested this effect may be attributed to the distinct functions of the proteins
hamartin and tuberin (42).
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Hamartin, tuberin, and the mTORC1 pathway
Though it was clear that hamartin and tuberin must either be binding partners or work
closely in the same biochemical pathway (43), it was not until later that the correct
relationship was elucidated. In a landmark study, tuberin was found to contain a binding
domain on its N-terminus with high affinity for a similar domain on hamartin (44, 45). In fact,
tuberin and hamartin form a heterodimeric coiled-coil complex, henceforth called the "TSC
complex," in which it is thought that the main function of hamartin is to stabilize tuberin (46,
47), whereas tuberin’s major known role lies in its GTPase-activating protein (GAP) domain
(25).
The most well-characterized function of the TSC complex is its inhibition of Rheb (Ras
homolog enriched in brain) via the GAP function of tuberin (48). Tuberin’s GAP domain is
located near its C-terminus and is indirectly responsible for hydrolyzing the conversion of
the Ras-related small G protein Rheb from its active GTP-bound state to its inactive GDPbound form (49) (Fig 1.1). Inactivation of Rheb, in turn, inhibits its ability to activate
mammalian target of rapamycin complex 1 (mTORC1), a distinct GβL/raptor (regulatory
associated protein of mTOR)-bound structure of the large serine-threonine protein kinase
mTOR (50). This process is achieved by antagonizing mTORC1's endogenous inhibitor
FK506-binding protein 38 (FKBP38) in a GTP-dependent manner (51). The TSC complex
therefore negatively regulates mTORC1 activation through Rheb.
It does so in response to four major signals – nutrient availability, growth factors,
energy status of the cell, and hypoxia. As amino acids are the building blocks of proteins,
mTORC1 activity is heavily regulated by amino acid sensing, as demonstrated in a study in
which withdrawal of amino acids from Drosophila and mammalian cells resulted in
attenuated mTORC1 signaling (52). However, recent work by Smith et al. (53) showed that
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*Fig 1.1. The mTOR network. (A) The mTOR kinase is the catalytic component of two
distinct multiprotein complexes called mTORC1 and mTORC2. (Left) In addition to mTOR,
mTORC1 contains RAPTOR, mLST8, and PRAS40. mTORC1 drives cellular growth by
controlling numerous processes that regulate protein synthesis and degradation. Diverse
positive and negative growth signals influence the activity of mTORC1, many of which
converge upon the TSC1/2 complex. (Right) mTORC2 also contains mLST8, but instead of
RAPTOR and PRAS40, mTORC2 contains the RICTOR, mSIN1, and PROTOR proteins.
(B) Model of mTORC1 co-regulation by RHEB and PRAS40. (Left) When AKT is inactive,
TSC1/2 inhibits RHEB while PRAS40 inhibits mTORC1. (Middle) Upon activation, AKT
promotes mTORC1 activity by phosphorylating both TSC1/2 and PRAS40. This results in
GTP-loading of RHEB, which directly activates mTORC1 and release of mTORC1 from
PRAS40 repression. (Right) In tsc2 null cells, RHEB strongly activates mTORC1. This in
turn inhibits AKT by way of the negative feedback loop. Even though PRAS40 is
dephosphorylated in this state, its ability to repress mTORC1 is overrun by the greatly
elevated Rheb activity.

* Figure and legend taken from (54). Legend has been slightly modified by deletion of
sentences that do not apply to my work. Permission to reproduce this figure in this thesis
has been requested and received from Elsevier, license number 2554090654204 to Sharon
Way.

9

10

amino acid withdrawal can affect mTORC1 signaling in cells lacking Tsc2, albeit to a lesser
degree than in a wild type cell. While this study revealed that amino acid sensing may occur
independently of TSC2, the TSC complex is one node by which nutrient signaling to
mTORC1 occurs.
Growth factor signaling to mTORC1, on the other hand, is closely regulated by the TSC
complex via phosphorylation of TSC2 by Akt, a major serine/threonine kinase involved in
multiple cellular processes. Akt is itself activated by PI3K, a signal transducer enzyme
which responds to insulin and growth factor presence in cell surface receptors (55, 56).
Binding of growth factors therefore results in phosphorylation of TSC2, which hinders the
function of the TSC complex in inhibiting mTORC1 via a mechanism that is still being
debated (57). In addition to Akt, Erk may also stimulate mTORC1 activity in response to
growth factors and cytokines via phosphorylation of TSC2 by RSK (p90 ribosomal protein
S6 kinase), which results in dissociation of TSC1 and TSC2 (58, 59).
Meanwhile, the TSC complex also plays an important role in energy and oxygen
sensing. When energy in the form of ATP is low, intracellular levels of AMP are increased
and bind to AMPK (AMP-dependent protein kinase) (60), which is then activated via
upstream kinases such as LKB1, a tumor suppressor associated with Peutz-Jeghers
sydrome. Activated AMPK then phosphorylates downstream targets such as TSC2 to
decrease energy-depleting processes (59, 61). Hypoxia has also been shown to
downregulate mTORC1 activity via AMPK (62), as well as through REDD1. REDD1, a
stress response gene, was first identified when its orthologues in Drosophila (scylla and
charybdis) were found to suppress an overgrowth phenotype caused by overactivation of
Akt (63). Later studies suggested that REDD1 inhibits mTORC1 activity by reversing Aktmediated inhibition of the TSC complex through removal of 14-3-3 (64), a signaling
regulator thought to be involved in Akt phosphorylation. By integrating these various
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signals, the TSC complex functions as a “central hub of signal transduction within the cell
(57)” to control mTORC1 activity.
The evolutionary-conserved mTORC1 pathway modulates a number of major
downstream processes that regulate cell growth and proliferation such as mRNA
translation, ribosome biogenesis, nutrient metabolism, and autophagy. Protein translation is
regulated by mTORC1 through phosphorylation of at least two known translational
regulatory proteins: the activation of p70 ribosomal protein S6 kinase-1 (S6K1) and
inhibition of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) (65). S6K1
regulates cell size via phosphorylation of 40S ribosomal protein S6, which is important in
translational control of mRNAs that contain a 5’-terminal oligopyrimidine tract (TOP). 4EBP1, on the other hand, inhibits eIF4E, which recruits 40S ribosomal subunits to the 5’ end
of mRNAs. Phosphorylation of 4E-BP1 by mTORC1 hence activates mRNA translation
(66). Mutations in either TSC1 or TSC2 therefore lead to constitutive activation of the
mTORC1/4E-BP1/S6K1 signaling pathway, resulting in dysregulated translation.

Drosophila Homologues of TSC1 and TSC2
Much of the knowledge regarding the functions of the TSC1 and TSC2 genes was first
elucidated from studies of the fruit fly, Drosophila melanogaster. The cells of the Drosophila
eye progress through the cell cycle in a continuum from anterior to posterior (67), making it
an excellent subject for study of the cell cycle. During a genetic screen to identify new
mutations affecting eye structure, Ito and Rubin (68) isolated several mutations that
produced enlarged cells and identified them as allelic to the previously characterized gigas
gene, a homolog of TSC2. Characterization of these alleles revealed that though they
undergo normal differentiation, cells undergo S phase without entering M phase and are
enlarged due to this cell cycle defect. Similar results were found in mutants of the
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Drosophila homolog of TSC1 in two independent studies (69, 70), both of which also
suggested a role for TSC1/2 in the insulin signaling pathway given the similarities between
mutants of each group. These and similar studies using Drosophila, like those described
previously, significantly advanced the understanding of the functions of TSC1 and TSC2
and served as a comparison for later findings in mammalian models of TSC.

Mouse Models of TSC Neuropathology
With the newfound understanding of the TSC1 and TSC2 genes from Drosophila
studies, researchers were eager to better understand the brain and other pathologies of
TSC using a mammalian model system by creating Tsc1 and Tsc2 knockout mice. The
importance of the mTORC1 pathway in prenatal development was quickly underscored,
however, when homozygous KO mice for both genes were found to be embryonic lethal.
Characterization of the Tsc1 KO mice revealed they died from liver hemangiomas, a
symptom both Tsc1 (71) and Tsc2 (72, 73) heterozygous KO mice exhibited, along with
kidney lesions. In addition, both heterozygotes were found with increased numbers of
astrocytes (74), suggesting a role for both hamartin and tuberin in astrocyte proliferation.
However, as little other brain pathology was seen, a conditional knockout allele was
eventually created of the Tsc1 gene using the Cre-loxP system.
This Tsc1-based conditional knockout (Tsc1 CKO) mouse has been independently
used to study two cell groups affected in TSC neuropathology: astrocytes and neurons. In
the astrocyte-specific Tsc1 CKO mouse (75), hamartin is deleted using a GFAP-Cre driver
beginning embryonic day 14.5 (E14.5) (76). These mice developed clinically obvious
seizures by 2 months of age and die by 22 weeks. These mice also displayed an increase
in brain size, increased astrocyte proliferation, abnormal neuronal organization in the
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hippocampus, and mTORC1 activation. The astrocyte-specific Tsc1 CKO mouse does not,
however, exhibit pathology similar to that seen in cortical tubers.
A neuron-specific Tsc1 CKO was created using a synapsin-Cre driver that deletes
hamartin beginning E13.0 (77). These mice exhibit a much more severe phenotype than
that seen in the astrocyte-specific Tsc1 model. They display neurological abnormalities
such as hyperactivity, enhanced startle response, and high-frequency trunk and limb tremor
as early as postnatal day 10 (P10). Neuron-specific Tsc1 CKO mice also display a failure to
thrive phenotype with a median survival of 35 days. Spontaneous and provoked seizures
were also observed, with some seizures ending in a fatal tonic phase. Compared to the
astrocyte-specific model, these mice also exhibit a more severe histologic phenotype in the
form of abnormal brain cytoarchitecture, enlarged and dysplastic neurons showing
activated mTORC1, and reduced myelination.
The astrocyte- and neuron-specific Tsc1 CKO mouse models have provided the TSC
field with valuable insight into TSC brain pathology, as they both exhibit features similar to
those seen in humans. In particular, the neuron-specific Tsc1 CKO provided support for the
LOH model of tumor formation in the TSC brain, as it models the human condition of one
general deletion of Tsc1 in all cells, with knockout of the second allele only in post-mitotic
neurons. Given the higher frequency and more severe nature of TSC2-based disease,
however, our laboratory sought to use a similar method to create a Tsc2-based conditional
allele with which TSC neuropathology might be studied. The creation and characterization
of this Tsc2-based conditional allele is the subject of Chapter 2 in this thesis.
Using this conditional allele, we also sought to establish a Tsc2-based mouse model of
the development of TSC neuropathology. Cortical tubers have been detected as early as
19-20 weeks in a human fetus, evidence that they are developmental lesions (78, 79).
Tubers also contain cells of mixed neuronal and glial lineage with loss of cortical lamination
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(16), suggesting that they arise from a neuronal-glial precursor that failed to properly
differentiate and migrate (80, 81). Radial glial cells are neuroglial progenitors that give rise
to the majority of neurons and astrocytes in the cortex. In addition, they form radial fibers
along the width of the developing cortex which are crucial to neuronal migration (82). We
therefore hypothesized that loss of TSC1 or TSC2 in radial glial cells may be a major
mechanism of TSC neuropathology. Using a radial-glia specific Cre driver, hGFAP-Cre (83,
84), we have tested this hypothesis in a Tsc2-based CKO mouse. This experiment is
discussed in depth in Chapter 3 of this thesis.

Rapamycin and the PI3K/Akt/mTOR pathway
Since inhibition of mTORC1 is the most well-characterized role of the TSC complex,
researchers speculated that treatment of patients with an mTORC1 inhibitor might rescue
formation of TSC pathology. The macrolide rapamycin, also known as sirolimus, was
suggested as a candidate. Originally used to probe mTOR (mammalian Target Of
Rapamycin) biology and crucial in elucidating the function of the mTOR pathway (85, 86),
rapamycin is an FDA-approved drug used as an immunosuppressant for kidney transplants
(87). Rapamycin inhibits mTORC1 via a mechanism similar to that of FKBP38 by forming a
complex with the intracellular binding protein FKBP12 (88). FKBP12 then binds to
mTORC1’s FKBP12-rapamycin binding domain to inhibit the ability of the kinase to signal to
its downstream effectors (89).
The ability of rapamycin to inhibit TSC-related pathology was first demonstrated in the
Eker rat. The Eker rat model of TSC harbors a spontaneous mutation that inactivates Tsc2
and is characterized by hereditary renal cell carcinoma (90). Immunohistological staining of
primary tumors from these rats demonstrated increased phospho-4E-BP1 and pS6K,
indicators of activated mTORC1 (91). Short-term treatment of the Eker rats with rapamycin
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resulted in induction of apoptosis and reduction of cell proliferation (92). Follow-up studies
addressing the pituitary tumors found in 58% of adult Eker rats showed that long-term
treatment with rapamycin reversed weight loss and abnormal gait while prolonging lifespan.
However, withdrawal of treatment resulted in further clinical deterioration of these rats.
Despite this potential drawback, these initial preclinical studies demonstrated that
rapamycin was a promising agent for the pharmacologic treatment of TSC. Preclinical
rapamycin treatment studies have been conducted in both the astrocyte- (93) and neuronspecific (94) Tsc1 CKO mouse models. In the former, early and late treatments with
rapamycin were tested. Early treatment, given from 2 to 7 weeks of age, was found to
prevent the development of epilepsy and premature death. Late treatment, given from 6
weeks to 9 weeks of age, was able to suppress seizures and prolonged survival in mice
that had already developed epilepsy. Rapamycin treatment also inhibited the mTORC1
activation, astrogliosis, megalencephaly, and neuronal disorganization initially reported.
Similar findings were observed in the neuron-specific Tsc1 CKO. Rapamycin treatment
resulted in improvement of the neurofilament abnormalities, cell enlargement, and
myelination defects, though the dysplastic features and abnormal dendritic spine density
and length originally described in the neurons were unaffected.
Taken together, these results suggest that rapamycin may have a large therapeutic
impact on TSC brain pathology. However, the latter findings regarding the minimal impact
rapamycin had on dendrites and neuronal morphology are particularly interesting. Though
the inhibitory role of the TSC complex on mTORC1 is well characterized, a number of
studies suggest that hamartin and tuberin have additional functions, both as a complex and
as individual proteins (42). While it is unknown how these alternate roles contribute to TSC
pathology, a steadily increasing body of findings such as those previously described
suggests mTORC1 alone cannot be solely responsible for all manifestations of TSC.
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For example, recent studies have shown that the TSC complex is also required for
proper activation of mTORC2 (95), a distinct, rapamycin-insensitive complex of the mTOR
protein that consists of the rictor/GβL-bound structure of the mTOR protein. mTORC2
activates Akt, giving it a firm role in the regulation of actin cytoskeleton and cell morphology
(96). As previously described, the Akt pathway is a key component of the insulin/PI3K
signaling pathway which modulates cell survival, actin formation, and proliferation. It has
also been identified as a major regulator of neuronal polarity, including axon and dendrite
formation (97, 98). Given that rapamycin had minimal impact on neuronal morphology and
dendritic spine density in the neuron-specific Tsc1 CKO mouse, it follows that these
aspects of TSC brain pathology might function through mTORC2 rather than mTORC1.
However, the downstream target of mTORC1, S6K1, is a known inhibitor of PI3K (99),
suggesting that increased mTORC1 signaling might also attenuate Akt signaling and affect
dendritic growth. In addition, prolonged treatment of rapamycin has been shown to inhibit
mTORC2 assembly and Akt signaling (100). The complex interplay between these two
pathways suggest that distinguishing between mTORC1 and mTORC1-independent
pathways may be more difficult than previously thought.
We have investigated some of these issues by examining the effects of low dosage
rapamycin treatment in our Tsc2-based mouse model. In addition to establishing whether
rapamycin is equally effective in Tsc2-mediated pathology, we have sought to explore the
impact of dosage as well as pre- versus postnatal administration of rapamycin. By treating
with rapamycin at different stages, we hoped to better understand the effects of drug
treatment on defects that occur prenatally or postnatally. As TSC is a neurodevelopmental
disorder, we were especially interested in assessing whether in utero rapamycin
administration might rescue defects that occur before birth. Given the complexities of the
PI3K/Akt/mTOR pathway as described above, we also hoped to determine the degree of

17

mTORC1-specific involvement in the various aspects of TSC brain pathology using
rapamycin as a direct inhibitor of mTORC1. The histologic outcomes of these experiments
are further explored in Chapter 4 of this thesis. The same treatment schemes are then used
in these mice to determine the functional impact of rapamycin rescue, as described in
Chapter 5.

Summary
From the first descriptions of TSC in the late 19th century to the relatively recent
discovery of the main pathway in which the TSC proteins function, our understanding of
TSC has increased exponentially. However, significant gaps still exist in our knowledge
regarding the pathophysiology of the disease. In this thesis, we sought to address some of
these unknowns through the creation and characterization of a novel neuro-glial conditional
knockout of the Tsc2 gene, which recapitulates many aspects of TSC neuropathology. We
then used this model to test the therapeutic potential of rapamycin to treat TSC brain
defects while elucidating the degree of mTORC1 involvement in formation of these lesions.
Chapter 2 will detail the creation of the Tsc2-based conditional allele and its characteristics.
Chapter 3 will describe the creation and characterization of our mouse model of TSC
neuropathology in which Tsc2 is deleted in radial glial cells. Chapter 4 will examine the
effects of treatment at different timepoints of these mice with rapamycin. These studies will
continue in Chapter 5, where functional rescue of TSC pathology following rapamycin
treatment will be examined via behavioral testing of these mice. Together, these studies
have contributed greatly to our current knowledge regarding the formation, characteristics,
and effects of treatment of TSC pathology in the brain.
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Chapter Two:
Creation and Characterization of the Tsc2flox/flox Mouse
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Introduction
It was well established that tuberin and hamartin formed a heterodimer to regulate
mTORC1, a function that was thought to be the main role of the two proteins and a major
mechanism of TSC pathology formation. However, much less was understood regarding
the functions of these proteins when individually bound to the other partners both were
shown to have (42). The fact that both tuberin and hamartin had other binding partners
strongly emphasized the need to investigate the individual contributions of both Tsc1 and
Tsc2 to TSC pathology. As characterization of Tsc1-based mouse models of TSC were
under way, researchers began attempts to create a Tsc2-based model for future
investigation.
Tsc2+/- mice (77) and Eker rats (101) demonstrated limited brain pathology with no
associated clinical phenotype. Similar to Tsc1 null mice (71), Tsc2 null mice were found to
be embryonic lethal (72, 73) and could not be used for study of advanced brain pathology.
However, study of Tsc2 null murine neuroepithelial progenitor cells (NEPs) demonstrated
that these cells displayed aberrant differentiation and represented giant cells found in
tubers, suggesting that biallelic inactivation of Tsc2 in the brain could provide a good model
system for the study of tuber pathogenesis (102). The need for a model in which Tsc2
could be conditionally knocked out in the brain was therefore clear. Our laboratory therefore
set out to create and characterize such a model.
When I began my doctoral studies, the laboratory had already created the Tsc2flox
mouse. Nonetheless, I helped characterize and establish that this strain would be a useful
reagent for cell specific Cre-mediated deletion (103). In the following chapter, I will
summarize previously conducted work in the methods section, while the work that I
contributed to in characterizing this Tsc2-based conditional knockout mouse will be
presented in the results section.
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Materials and Methods
Generation of a Conditional Disruption of the Tsc2 Gene – As described in Hernandez
et al. (103), the Cre-loxP and Flp-frt systems were used to create a floxed Tsc2 allele.
(We made a Tsc2neo targeting vector by inserting a loxP-BamHI site
into intron 4 and a loxP-frt-neo-frt cassette into intron 1 (Fig 2.1a). To
screen for neomycin resistant ES cells we used the 3’ external and 5’
internal probes indicated. Seven of 180 clones demonstrated 13 kb
wildtype and 8.6 kb mutant bands on Southern blot when the genomic
DNA was digested with BamH1 and probed with the external probe (Fig
2.1b). After Southern analysis of BamHI-digested DNA using the
internal probe demonstrated the correct 13 kb wildtype and the 2.6 kb
mutant bands (Fig 2.1b), two of the clones were selected for blastocyst
injection. Only one chimera demonstrated germline transmission as
demonstrated by PCR genotyping for the presence of the loxP-BamH1
site (Fig 2. 1c). ...To generate a conditional allele of Tsc2 that would be
useful for modeling the multiorgan pathology of TSC in the mouse, we
removed the neomycin gene by mating the Tsc2+/neo to FLPe transgenic
mice (Fig 2.2a) (104). We conﬁrmed that the neomycin gene was
removed by PCR detection of the loxP-frt site that remains after Flp
recombination (Fig 2.2b). To demonstrate that the Tsc2flox allele could
be converted to a null allele by Cre recombination, we mated the
Tsc2flox/flox mice with a CMV-Cre transgenic mouse (Fig 2.2a). Complete
deletion of exons 2–4 was demonstrated by PCR genotyping (Fig 2.2c).
(100)

Embryo and Adult Organ Analysis – All animal procedures were approved by the
University of Texas Health Science Center Animal Welfare Committee. For embryonic
analysis, the day the vaginal plug was found was considered embryonic day 0.5. Dams
were anesthetized using 2.5% avertin and killed via cervical dislocation before embryos
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†Figure 2.1. Generation of the Tsc2neo allele. (a) Gene-targeting construct. Exons are
indicated by black boxes labeled with exon numbers. LoxP sites are marked by black
triangles and frt sites by white triangles. The loxP-frt-neo-frt cassette was inserted in intron
1 and a loxP-BamHI site in intron 4. External and internal probes used for ES cell screening
are indicated. PCR primers P1F and P1R were used to conﬁrm germline transmission of
the Tsc2neo allele. B, BamHI; A, AflII; S, SbfI. (b) Southern blot analysis of genomic DNA
digested with BamHI from Tsc2+/+ and Tsc2+/neo ES cell clones and probed with the external
probe (Probe A). Positive clones (Lanes 1, 3) demonstrate the shorter 8.6 kb band because
of the introduced BamHI site. Hybridization using the internal probe (Probe B) shows 13
and 2.6 kb fragments for both Tsc2+/neo clones (Lanes 1,2). (c) PCR product from mouse
DNA using Primers P1F and P1R. Lane 1 shows a heterozygote Tsc2+/neo with a 433bp
loxP-BamHI allele and a 389bp wild type allele; Lane 2, homozygous Tsc2neo/neo embryo
DNA; Lane 3 wild type.
†Figure and legend taken from (103). All figures and legends in this chapter are taken from
a previous publication in which I was the second author. Guidelines from this journal do not
require permission to reproduce manuscript content as part of a thesis, as described in this
website: (http://authorservices.wiley.com/bauthor/faqs_copyright.asp#1.7)
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†Figure 2.2. Generation of the Tsc2flox and Tsc2ko alleles. (a) The Tsc2neo allele was
converted to a ﬂoxed allele by mating with a FLPe transgenic mouse. Heterozygous and
homozygous Tsc2flox mice were obtained at the expected Mendelian frequencies, and
homozygous mice were viable and fertile. A Tsc2ko allele was generated by mating the
Tsc2flox mice with a general Cre-deletor strain. (b) PCR of tail DNA from conditional
knockout mice using primers P2F and P2R. The 1172bp band indicates the presence of the
loxP-frt site while the 1000bp band represents a wildtype allele. (c) PCR of tail or embryo
DNA using primers P4F, P3R, and P3F to detect the wild type and the Tsc2ko alleles. The
1090 bp band represents the null allele. Homozygous Tsc2ko/ko genotypes were only
identiﬁed at embryonic time points due to the lethality of the null phenotype (Lane 3).

†Figure and legend taken from (103).
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were extracted and placed into cold 1 x PBS. Yolk sacs or a small part of each body were
taken for genotyping. Embryos were then fixed for 4-6 hours in 4% paraformaldehyde
(PFA) and stored in 70% ethanol prior to staging. Adult mice were transcardially perfused
with ice-cold 1 x PBS followed by 4% PFA. Organs were extracted and post-fixed overnight
in 4% PFA before storage for a minimum of one day in 70% ethanol. Organs were then
dehydrated, embedded in paraffin and sectioned at 5 µm on a microtome. Slides were
rehydrated and stained with hematoxylin and eosin then protected with a coverslip. Organ
sections were visualized with an Olympus BX51 light microscope while all images were
captured using a SPOT RT digital camera.

Immunoblotting – Embryos were extracted from dams as described above and the yolk
sac or a hindlimb taken for genotyping. Embryos were then snap frozen in liquid nitrogen,
and following genotype identification, pooled by genotype and homogenized with 10
volumes of RIPA buffer and protease inhibitor (Sigma) in a dounce homogenizer. Lysates
were centrifuged for 10 min at 4˚C, sonicated to ensure complete homogenization, and
frozen until use. A BCA reagent kit (Pierce) was used to determine protein concentration.
Samples were diluted using Laemmli SDS-sample buffer and separated by electrophoresis
on a 4-12% bis-tris gel (Invitrogen) before being transferred to a nitrocellulose membrane.
The same membrane was sequentially probed with three different antibodies with a
stripping step in between each probe. Antibodies used, in order, were tuberin (1:1000, Cell
Signaling), hamartin (1:1000, Santa Cruz), and phosphorylated (Ser 240/244) S6 (1:2000,
Cell Signaling). Secondary antibodies were conjugated with horseradish peroxidase and
visualization of proteins was conducted using the Amersham ECL kit.
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Results
Tsc2neo/neo mice are embryonic lethal
Tsc2+/neo mice were initially generated as an intermediate step before producing the
desired Tsc2+/flox mice. However, though Tsc2+/neo mice were viable and fertile, matings
between Tsc2+/neo mice did not generate any liveborn Tsc2neo/neo pups, indicating that the
homozygous state was lethal. Initial studies at embryonic day 12.5 (E12.5) revealed a
number of embryos that were smaller, paler, and less developed than their littermates, as
well as a number of resorptions. One of these smaller embryos was even found with an
open neural tube (Fig 2.3b). Though the resorptions did not yield enough DNA to genotype,
the smaller embryos were mainly found to be Tsc2neo/neo. Further characterization of litters
at E11.5, 12.5, 13.5, 15.5, and 17.5 established that Tsc2neo/neo mice were embryonic lethal
around E12.5 (Fig 2.3c).

The Tsc2neo allele is hypomorphic
The above results are similar to those found in other Tsc2 null mutants. Onda et al.
(72) demonstrated that their Tsc2 null mouse mutants died at E9.5-12.5, though they did
not find any null embryos after E12.5. Meanwhile, Tsc2 null mutants generated by
Kobayashi et al. (73) died around E10.5, with no null embryos found after E13.5. Given that
we were able to find Tsc2neo/neo mutants up until E17.5, we suspected that the Tsc2neo allele
might be hypomorphic. This hypothesis was confirmed biochemically using immunoblots.
Western analysis of whole embryos at E12.5 (Fig 2.3a) confirmed that expression of the
Tsc2 protein tuberin was significantly decreased, but not completely lost, in the Tsc2neo/neo
embryos as compared to the Tsc2+/neo or Tsc2+/+. However, expression of pS6, an indication
of mTORC1 activation, was similar between the homozygous and heterozygous alleles,
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†Figure 2.3. Analysis of Tsc2neo allele. (a) Western analysis of lysates from E12.5
embryos. Note the low level of tuberin antigen in the Tsc2neo/neo lane. Hamartin levels are
unaffected. Phosphorylated S6 is increased in both Tsc2+/neo and Tsc2neo/neo lysates. (b)
Comparison of embryos at E12.5. Tsc2neo/neo embryos were slightly smaller than wildtype
and were distinctly underdeveloped and pale. Most noticeable is the lack of digitation of
paws and the head size. Note the open neural tube indicated by the arrows. (c) Genotype
frequency of Tsc2+/neo crosses demonstrating the lethality of Tsc2neo/neo embryos. Asterisk
(*) denotes nongenotypable resorptions. (d) Kidneys from Tsc2+/neo mice at various ages
demonstrating cysts, and an H and E histology of a simple cyst, demonstrating renal cyst.
Bar represents 1 mm for gross kidney photographs. (e) Table characterizing the kidney cyst
phenotype. Note that no cysts developed in the ﬁrst year of life, most cysts were 1 mm or
less. No tumors were detected.

†Figure and legend taken from (103).
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suggesting that presence of the neo cassette on Tsc2 was sufficient to disrupt its inhibition
of mTORC1, verifying that the Tsc2neo allele was indeed hypomorphic.

Tsc2+/neo mice develop renal cysts but not carcinomas
Kobayashi et al. (73) reported that their Tsc2+/KO mice displayed renal carcinomas
(RCs) that were mainly cystic as early as 14 weeks and in almost all mice by 6 months. The
Tsc2 heterozygous allele studied by Onda et al. (72) displayed multiple bilateral renal
cystadenomas, or lesions containing solid adenomas and pure cysts, with 100%
penetrance by 15 months of age. Though these cysts progressed to RCs in only 10% of the
mice, the group found an average of 100 cystadenomas per kidney in 15 month old mice.
However, outbreeding this allele to a different mouse strain resulted in a less severe
phenotype, which may explain the differences in renal lesion severity found between these
two groups.
We sought to compare the renal phenotype of our Tsc2+/neo mice to those reported.
Though older Tsc2+/neo mice appeared healthy, we noticed that a majority had renal cysts
(Fig 2.3d) after one year of age (Fig 2.3e). These cysts mainly appeared as single lesions
on each kidney, though mice 16 months and older demonstrated multiple lesions that were
larger than those found in younger mice. Systematic analysis of kidneys of 15 mice of
different ages revealed that the number and size of cysts were indeed increasing with age
in the Tsc2+/neo mice (Fig 2.3e). We did not find any frank renal tumors in these mice before
the study ended at 20 months of age. Cysts were also not detected in any Tsc2+/+ mice.
The presence of a milder renal phenotype in our Tsc2+/neo mice provides further evidence
that the Tsc2neo allele is hypomorphic.
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†Figure 2.4. Comparison of organs of wild type vs Tsc2flox/flox mice. Tsc2+/+:
a,c,e,g,I,k; Tsc2flox/flox: b,d,f,h,j,l. (a,b) Cerebral cortex. (c,d) Hippocampus. (e,f) Cerebellum.
(g,h) Liver. (I,j) Lung. (k, l) Kidney. Magnification: 40x (a-d); 200x (e-l).

†Figure and legend taken from (103).
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Tsc2flox/flox mice are viable, fertile, and pathologically indistinguishable from wildtype
mice
The Tsc2flox allele was generated by mating the Tsc2+/neo mouse with an FLPe
transgenic mouse, resulting in excision of the neomycin cassette. Heterozygous Tsc2+/flox
and homozygous Tsc2flox/flox mice were viable, fertile, and born in the expected Mendelian
ratios. To establish that the presence of loxP sites, located upstream of exon 1 and
downstream of exon 4, did not affect major organs, we studied 5 µm paraffin-embedded
sections of the Tsc2flox/flox cortex, hippocampus, cerebellum, liver, lung, and kidneys that
were routinely stained with H&E. As we found no noticeable differences compared to
similar tissue samples from Tsc2+/+ littermates (Fig 2.4), we concluded that the Tsc2flox/flox
mouse could be used for future studies using organ or tissue-specific Cre-mediated
deletion with confidence.

Embryonic and renal phenotypes in Tsc2 KO mice are similar to those previously
reported
To verify that the loxP sites were functional and would generate a null allele following
Cre recombination, we mated the Tsc2flox/flox mouse with a CMV-Cre transgenic mouse that
expresses Cre in all cell types. Tsc2KO/KO mice demonstrated midgestation lethality (Fig
2.5c) like the Tsc2neo/neo mice, though at the earlier timepoint of E10.5-E11.5. While
Tsc2KO/KO embryos were still detectable at E12.5, they were severely underdeveloped
compared to Tsc2+/KO and Tsc2+/+ littermates. Comparison of the Tsc2neo/neo (Fig 2.3b) and
Tsc2KO/KO embryos at this timepoint underscores the hypomorphic status of the Tsc2neo
allele as well as the importance of Tsc2 in development. Western blot analysis of E12.5
Tsc2 null embryos confirmed absence of tuberin and significant expression of pS6, while

29

†Figure 2.5. Analysis of the Tsc2ko allele. (a) Western analysis of E12.5 embryo lysates.
Note the absence of tuberin in Tsc2ko/ko lysates, with the preservation of hamartin levels in
all genotypes. Phosphorylated S6 is increased in Tsc2+/ko and even more so in the Tsc2ko/ko
lysates, demonstrating activation of the mTOR pathway. (b) Comparison of embryos at
E12.5. Wildtype and Tsc2+/ko mice are virtually identical. The Tsc2ko/ko mouse is severely
growth retarded. (c) Genotype frequency of Tsc2+/ko crosses demonstrating the lethality of
Tsc2ko/ko. Asterisk (*) denotes non-genotypable resorptions. (d) Kidney phenotype. Note
the multicyst development (white arrows) in Tsc2+/ko mice. A small tumor is indicated by the
black arrowhead. (e) A large tumor was found in a Tsc2+/ko mouse at 11 months of age. (f)
Histology of a complex cyst. (g) Histology of tumor shown in panel e. Note the presence of
giant cells and nuclei (white arrowheads). (h) Table characterizing the kidney phenotype.
Note that cysts as well as tumors were detected within the ﬁrst year of life, much sooner
than with the Tsc2neo phenotype.

†Figure and legend taken from (103).
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Tsc2+/KO samples also demonstrate a slight increase in pS6 levels compared to the Tsc2+/+
(Fig 2.5a).
Analysis of Tsc2+/KO kidneys revealed a more severe phenotype than that seen in
Tsc2neo/neo mice, with multicyst formation found in a majority of mice as early as 7 months of
age (Fig 2.5d). By 9 months, the renal cyst phenotype was 100% penetrant (Fig 2.5h).
Though cystadenomas made up the majority of renal lesions found (Fig 2.5f), several small
tumors were found in various kidneys with one large tumor (Fig 2.5e) found in an 11 month
old mouse. Histologic analysis of this tumor revealed enlarged cells and nuclei (Fig 2.5g).
Taken together, these kidney and embryo findings are similar to those demonstrated in
Tsc2+/KO mice characterized by Onda et al. (72) and Kobayashi et al. (73), confirming that
the Tsc2flox allele may be used for Cre-mediated deletion of Tsc2.

Discussion
Our lab has created and characterized a novel Tsc2 conditional allele using the CreloxP system (103). We have shown that the Tsc2flox/flox mice are viable, fertile, and
histologically similar to wild type mice. We have also demonstrated that the Tsc2flox allele is
effectively converted to a null mutation upon Cre-mediated recombination, as evidenced by
the similarities between Tsc2+/KO mice generated using our Tsc2flox/flox and previously
reported Tsc2+/KO phenotypes. This Tsc2flox/flox allele will be a valuable tool for determining
the role of tuberin in various organ systems, as well as for comparing the individual roles of
hamartin and tuberin in TSC pathology.
In the process of creating this Tsc2 conditional allele, we have also generated a
hypomorphic allele, Tsc2neo, in which a neomycin cassette is present between exons 1 and
2 of the Tsc2 gene. Although the neo cassette is present in intronic space, presence of this
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cassette has been shown to disrupt normal splicing patterns or cause premature transcript
termination (105-108). These events often result in attenuation of gene expression or
function, as evidenced in the Tsc2+/neo mice, which demonstrate a milder version of similar
clinical manifestations compared to Tsc2+/KO mice. These Tsc2+/neo mice may be particularly
useful for the study of a milder form of TSC found in patients, which has been associated
with Tsc2 missense mutations (109-111). A number of Tsc2 missense mutations result in
the expression of a stably expressed mutant form of tuberin which can still form a complex
with hamartin and appears to have partial function (37, 112). Investigation of the Tsc2+/neo
mice may establish a role for hypermorphic alleles with partial function in causing a milder
clinical form of TSC (113).
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Chapter Three:
Creation and Characterization of the Tsc2flox/ko; hGFAP-Cre Mouse

All figures, legends, and the methods section of this chapter are taken or modified from a
previous publication in which I was the first author. Guidelines from this journal do not
require permission to reproduce manuscript content as part of a thesis, as described in this
website: (http://www.oxfordjournals.org/access_purchase/publication_rights.html)
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Introduction
Following the creation of the Tsc2-based conditional knockout allele (see Chapter 2),
we sought to develop a Tsc2-based model of TSC neuropathology. Previous studies in
mouse models showed that conditional deletion of Tsc1 in mature astrocytes resulted in
increased brain size, proliferation of astrocytes, abnormal neuronal organization, and
clinically obvious seizures, with a median survival of 11-12 weeks (75). Meanwhile, deletion
of Tsc1 in post-mitotic, mature neurons using the same conditional allele resulted in a much
more severe phenotype, including megalencephaly, enlarged, dysplastic, and ectopic
neurons, reduced myelination, spontaneous or provoked seizures, and a median survival of
35 days (77). Taken together, both models replicate a number of important features of TSC
brain pathology in humans. However, individually, neither fully recapitulate the main
characteristics of the disease.
This finding may be due to the fact that the deletions generated in these mouse models
were all in post-mitotic, differentiated cells. As TSC is a developmental disease and “(the
cytoarchitecture of cerebral cortex surrounding tubers is typically normal,” it is likely that
“(tubers result from a developmental defect that affects a restricted population of neuronal
precursor cells during corticogenesis (21) (emphasis added).” Indeed, given that cortical
tubers and supependymal nodules (SENs) contain semi-differentiated cells that contain
both astrocytic and neuronal markers (16), inactivation of Tsc1 or Tsc2 likely occurs predifferentiation in a neuronal-glial precursor cell.
In 2001, Noctor et al. (82) established that radial glial cells, long thought to be glial
progenitors that were mainly used as scaffolding for migrating neurons generated
elsewhere (114), were in fact neuroglial progenitor cells. Their study also confirmed the
presence of a “lineage relationship between neurons and proliferative radial glia” in which
“local clonal relationships in the embryonic ventricular zone can be translated into functional
34

columnar units in the adult neocortex (82).” As radial glia are progenitor cells that produce
both neurons and glia, defects in the differentiation process in these cells may result in
daughter cells that are semi-differentiated. Migrational defects in both neuronal and glia
populations may also result should problems with the radial glial fibers that form the
scaffolding for migration occur. Finally, as radial glial daughter cells form the columnar units
found in the neocortex, issues with the mother cell may result in structural problems for the
entire columnar unit. Taken together, these findings strongly indicate that radial glial cells
are an excellent candidate for the origin of tubers, and perhaps other TSC brain lesions.
To test the neuroglial hypothesis of TSC neuropathology, we crossed an hGFAP-Cre
(human glial fibrillary acidic protein) transgenic mouse (83, 84), in which Cre expression is
confined to radial glial cells, with our floxed Tsc2 allele (described in Results). The resulting
Tsc2flox/ko;hGFAP-Cre mouse models many prominent features of TSC brain pathology,
including defects in cell size, migration, myelination, and astrogliosis. Compared to the
Tsc1-based astrocyte- and neuron-specific models, our Tsc2flox/ko;hGFAP-Cre mouse has a
more severe phenotype with greater representation of human TSC characteristics.
Therefore, this model demonstrates a likely role for radial glia as an origin of TSC brain
pathology and provides a good model for the study of TSC neuropathology.

Materials and Methods (taken from (115)

Mice and genotyping – All animal experimentation was approved by
the UTHSC Animal Welfare Committee. Mice were in a mixed 129 and
C57/Bl6 background. Tsc2+/flox, Tsc2+/ko and hGFAP-Cre mice have
been previously described (83, 84, 103). Mice were genotyped for Tsc2
alleles

using

three

primers

in

one

PCR

reaction:

KO1:

5’-

GCAGCAGGTCTGCAGTGAAT-3’, KO2: 5’-CCTCCTGCATGGAGTTGAGT-3’; WT2: 5’-CAGGCATGTCTGGAGTCTTG -3’. Band sizes were
35

wild-type (390 bp), Tsc2flox (434 bp) and Tsc2ko (547 bp). Cre primers:
CreF: 5’-GGACATGTTCAGGGATCTCCAGGC-3’, CreR: 5’-CGACGATGAAGCATGTTTAGCTG-3’,

RapA:5’-AGGACTGGGTGGCTTCC-

AACTCCCAGACAC-3’, RapB: 5’-AGCTTCTCATTGCTGCGCGCCAGGTTCAGG-3'. Band sizes were Cre (219 bp) and Rap (590 bp) as a
positive control band. Cre and Rap primers were generously provided
by the laboratory of Richard Behringer.

Histological studies – Adult mice were deeply anesthetized before
undergoing transcardiac perfusion with PBS and then with 4%
paraformaldehyde (PFA). Mouse brains were post-fixed in PFA
overnight and stored in 70% ethanol prior to embedding in paraffin.
Paraffin blocks were sectioned at 5 µm. For embryo analysis, the day
the vaginal plug was seen was considered embryonic day 0.5. Dams
were anesthetized with 2.5% avertin and killed by cervical dislocation
before embryos were dissected into cold PBS and staged. A small
piece of the embryo was used for genotyping. Embryos were fixed in
PFA 4–6 h and washed in 1xPBS before being stored in 70% ethanol
and embedded in paraffin. Slides were rehydrated, stained with routine
H&E, and protected with a coverslip. Immunofluorescence was
performed by blocking in 10% serum from animal in which secondary
antibody was raised and 0.05% Triton X-100 in 1 x PBS for 1 h. Primary
antibody was allowed to incubate overnight at 4˚C. Sections were
washed in 1 x PBS followed by secondary antibody incubation for 1 h.
Tissue was directly visualized for fluorescence-conjugated secondary
antibodies. For adult BrdU analysis, pregnant dams were injected at
E15.5 with 10 mg/ml of BrdU dissolved in 0.01 M NaOH in dH2O. Brains
from resulting pups were isolated and embedded as described above.
Immunohistochemistry was also performed as described , though
sections were incubated for 20 min in 2 N HCl prior to blocking, and
visualization was achieved using a Vectastain Elite ABC Kit (Vector
Labs, Burlingame, CA) followed by incubation in SigmaFAST DAB
metal enhancer (Sigma, St. Louis, MO). For BrdU pulse-labeled

36

embryos, pregnant dams were injected 30 minutes before embryo
extraction, and BrdU was visualized via immunofluorescence. Tissue
images were examined using an Olympus BX51 or IX81 microscope
and captured with a Qimaging RETIGA-2000RV digital camera or a
Bio-Rad 1024 MP confocal microscope. Digital images were then
processed using Adobe Photoshop (Version 6.0, San Jose, CA, USA).

Antibodies – The antibodies used for immunohistochemistry were as
follows: Pax6 (1:2000, Developmental Studies Hybridoma Bank, Iowa
City, IA, USA), phosphorylated (Ser 240/244) S6 (1:100, Cell Signaling
Technology,

Bedford,

MA,

USA),

Cux-1

(1:50,

Santa

Cruz

Biotechnology, Santa Cruz, CA, USA), FoxP2 (1:4000, Abcam,
Cambridge, MA, USA), BrdU (1:50, Becton Dickinson, San Jose, CA,
USA), GFAP (1:400, Sigma), CC1 (1:5, Calbiochem, Gibbstown, NJ,
USA), S100 (1:100, DakoCytomation, Denmark and 1:500, Abcam),
PCNA (1:50, Santa Cruz) and NeuN (1:100), Tbr2 (1:2000), Tbr1
(1:500) and MBP (1:200) from Millipore, Billerica, MA, USA. Prolong
Gold antifade reagent with DAPI (Invitrogen, Eugene, OR, USA) was
used for DAPI staining and coverslipping of post-natal tissue.
Embryonic tissue was stained with Hoechst 33258 (Invitrogen) after
removal

of

the

Fluoromount-G

secondary

antibody

(SouthernBiotech,

and

Birmingham,

coverslipped
AL,

using

USA).

The

antibodies used for immunoblotting were: tuberin (1:1000), hamartin
(1:1000), pS6 (1:2000) and a-tubulin (1:1000), from Cell Signaling.

Quantitative analysis – Two or three serial sections from each mouse
were used for analysis unless otherwise noted. For post-natal cell
counts,

equal-sized

images

spanning

the

thickness

of

the

somatosensory cortex were taken at the same lateral distance from the
midline. Count results were corrected to represent a percentage of cells
in the cortex in order to account for differences in total cortex size. For
embryo counts, equal-sized images spanning most of the length of the
lateral ventricles were used. Marker-labeled cells with visible nuclei
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were manually counted using Photoshop and ImageJ (v1.38x, W.
Rasband, National Institutes of Health, Bethesda, MD, USA). For
neuron cell size determination, the cortex was divided into five equal
bins from the bottom of Layer I to the bottom of Layer VI. In one section
each from three pairs of control and mutant mice, 50 NeuN-labeled
neurons from Bin 3 were outlined and filled using Photoshop and area
was analyzed in micrometers using ImageJ. For DG area calculation,
one section each from three pairs of mice were stained with H&E. DG
cell images were captured using a 60x objective and cells near the
midline of the DG were outlined for area calculation in the same
manner. Data were analyzed using repeated-measures ANOVA in
SPSS (Version 16.0.2, Chicago, IL, USA) and Microsoft Excel (Version
2003, Seattle, WA, USA).

Protein analysis – Whole cell lysates were made from P21 cerebral
cortex and hippocampus that were quick-frozen in liquid nitrogen.
Samples were homogenized in a dounce homogenizer with 10 volumes
of Ripa buffer with protease inhibitor cocktail and phosphatase inhibitor
cocktail (Sigma). Lysates were centrifuged at 4˚C, sonicated and frozen
until use. Protein concentrations were determined with a BCA reagent
kit (Pierce, ThermoFisher Scientific, Rockford, IL, USA). Equal amounts
of protein were separated on a denaturing 4–12% gradient gel
(Invitrogen) and transferred to nitrocellulose. The membrane was cut
into sections and each section probed with different antibodies using a
stripping procedure after each experiment if necessary. Secondary
antibodies were horseradish peroxidase conjugated. Visualization was
conducted with an ECL kit (Amersham, Piscataway, NJ, USA). (115)

Results
Generation of Tsc2flox/ko;hGFAP-Cre mice
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Tsc2flox/ko;hGFAP-Cre (mutant) mice were generated by mating male Tsc2+/ko;hGFAPCre mice with previously characterized Tsc2flox/flox females (103). This mating scheme was
chosen to better model Tsc2 deletion in TSC patients, in whom inactivation of one allele of
Tsc2 occurs in all cells and a second hit is thought to be necessary for pathology formation
in a given organ (4). In our model, mice are born with one inactivated allele of Tsc2 in all
cells throughout the body, while the second somatic cell loss occurs only in radial glial cells
where Cre is expressed. Cre expression begins at embryonic day 12.5 (E12.5) in the
hippocampal anlage, as extensively characterized by Zhuo et al. (83) and Maletesta et al.
(84). Though these studies found that Cre activity begins at E13.5 in the cortex, further
studies have since demonstrated that Cre may be present as early as E12.5 in cortical
neurons and glia (Seonhee Kim, unpublished observations). Radial glial cells and their
progeny, which include the majority of neurons and glia in the cortex and hippocampus (82),
are therefore the only cells in this mouse with complete loss of Tsc2. Though loss of
heterozygosity (LOH) has been previously demonstrated in most TSC-associated lesions in
the heart, kidneys, and lungs (4, 116), little evidence of LOH in cortical tubers has been
found (31, 32, 117). Investigators have hence suggested that tuber formation may not
require loss of both alleles or that "only a subgroup of cells within a tuber is affected by a
second hit (4)." Characterization of this mouse model therefore also serves to demonstrate
whether LOH may lead to formation of TSC-like neuropathology.

Tsc2flox/ko;hGFAP-Cre mice exhibit a failure-to-thrive phenotype and die of seizures
by P23

Tsc2flox/ko;hGFAP-Cre mice were born in the expected Mendelian ratio
and appeared healthy until about post-natal day 8, when their weight
gain slowed compared with littermate controls (Fig 3.1A). By weaning,
Tsc2flox/ko;hGFAP-Cre mice were severely runted (Fig 3.1B) and died
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‡Figure 3.1. Generation of Tsc2flox/ko;hGFAP-Cre mice. (A) Weight curves of mutant
(Tsc2flox/ko;hGFAP-Cre) mice (red, n= 17) compared with the control (Tsc2+/flox) mice (blue, n
=15) demonstrating the retarded growth of the mutant animals. (B) A runted mutant, 21day-old (P21) mouse compared with a control littermate. Note the domed head and splayed
feet in the mutant animal. (C) The brain of the mutant mouse (right) was noticeably larger
than the control (left). (D) Ventricles in the mutant mouse were dilated (right). (E)
Immunoblot analyses of cortical and hippocampal lysates from mutant (‘Cre+’) mice
demonstrated a marked decrease of tuberin, slightly decreased levels of hamartin and large
increase in pS6 levels compared with the control (‘Cre-’). α-Tubulin was used as the loading
control. (F and G) Pax6 and pS6 immunohistochemistry in E15.5 control (F) and mutant (G)
mice showed increased activation of mTORC1 in the radial glial cells of the developing
cortex. Scale bars, C, 1 µm; F and G, 10 µm.
‡Figure and legend taken from (115).
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between 3 and 4 weeks, likely from seizures, as we observed several
mice seizing (n=6) and the majority of dead mice were found in
extensor posturing. The Tsc2flox/ko;hGFAP-Cre mice had splayed feet,
domed heads, and were often tremulous and generally less active than
littermate controls (115).

Though the mutant mice failed to gain weight after postnatal day 8 (P8), they had milk
in their stomachs as neonates and were seen suckling after P8. Though the actual amount
of food eaten was not measured, they were also observed feeding normally as late as P21,
suggesting the weight issue was not due to lack of food intake. By weaning at P21, most
mutant mice were sick-looking and spent the majority of their time hunched over.
Interestingly, no mutants were observed having seizures that did not end in death, which
occurred at a median age of P23 (n=20). Due to the lethality soon after weaning, all
analyses were carried out at P21 unless otherwise specified.

Tsc2flox/ko;hGFAP-Cre mice have enlarged brains that demonstrate loss of tuberin
Gross examination of the Tsc2flox/ko;hGFAP-Cre mouse brains revealed that they were
enlarged compared to control brains (Fig 3.1C). Low magnification coronal sections through
the lateral ventricles (Fig 3.1D) demonstrate a visible increase in thickness of the cortex,
though the increase in brain width appears to be more dramatic posteriorly. Enlargement of
the ventricles is also noticeable, suggestive of hydrocephalus.
To demonstrate extensive loss of tuberin, western analysis of cell
lysates from P21 cortex and hippocampus of the Tsc2flox/ko;hGFAP-Cre
and control mice was performed and demonstrated significant loss of
tuberin antigen (Fig 3.1E). Hamartin levels were also slightly decreased
in experimental lysates, reflecting the dependence of its stability on the
presence of its binding partner tuberin (46). Loss of tuberin antigen
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was accompanied by an expected activation of the mTORC1 pathway
based on increased levels of phosphorylated (Ser 240/244) S6 (pS6).
We then demonstrated that mTORC1 was activated in radial glia by
performing immunohistochemistry on E15.5 brains using antibodies
against the radial glial marker Pax6 and pS6 (Fig 3.1F, G) (118). In the
mutant embryonic brains, more intensely red pS6 staining was seen
surrounding the green Pax6-labeled nuclei of radial glial cells in the
ventricular zone compared with the control. This increased pS6
expression in radial glial cells demonstrated activation of mTORC1
caused by loss of Tsc2. (115)

Loss of Tsc2 in radial glia causes cortical enlargement, lamination defects, and
increased cell size in Tsc2flox/ko;hGFAP-Cre mice
Closer histological examination of coronal sections of the control and mutant mouse
brains confirmed that the mutant cortices were significantly thicker compared to the control
(Fig 3.2A, B; 1.91 mm vs 2.65 mm, P < 0.0005). Lamination defects were also pronounced
in the mutant, in which the normally clearly-demarcated cortical layers were blurred. This
finding is most noticeable in the usually cell-sparse and well-defined marginal zone adjacent
to the pial surface, also known as Layer I, which is poorly delineated in the mutant cortex.
Higher magnification of H&E-stained sections revealed significantly enlarged cells (Fig
3.2C-E, P < 0.005) in the mutant compared to the control. Though the nuclei of these cells
appeared larger, closer observation also revealed enlarged vacuoles (data not shown), a
possible indication of increased autophagy. The cells in the mutant cortex also appeared
less densely packed compared to the control, suggesting an increase in extracellular matrix.

The loss of Tsc2 in radial glia should have activated mTORC1 in all
their neuronal and glial progeny, similar to what has been observed in
human TSC lesions (119, 120). To assess cortical neuronal and
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‡Figure 3.2. Cerebral cortical defects and up-regulation of mTORC1 in cortical
neurons and astrocytes in Tsc2flox/ko;hGFAP-Cre mice. All sections were taken from P21
mice. (A and B) The cortex of the mutant (B) was thicker than the control (A) and displayed
lamination defects, blurring between the gray–white junction, and a much less-deﬁned
molecular layer (Layer I). (C and D) Higher magniﬁcation revealed enlarged cells in the
cortex of the mutant (D) and more extracellular matrix between the cells compared with the
control (C). (E) Comparison of the areas of NeuN-labeled neurons from mutant and control
cortex revealed that mutant neurons are signiﬁcantly larger (**P<0.005, n = 6) than control
neurons. (F and G) NeuN-labeled neurons in the mutant cortex (G) displayed substantial
increase in pS6 expression compared with the control (F), indicating elevated mTORC1
activation. (H and I) S100-labeled astrocytes in the mutant cortex (I) also showed notable
increase in pS6 expression compared with the control (H). Scale bars, A and B, 100 µm; C
and D, 20 µm; F and G, 50 µm; H and I, 40 µm, inset 10 µm.
‡Figure and legend taken from (115).
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astrocyte

mTORC1

activation,

we

performed

double

immunohistochemistry against NeuN, a neuronal marker, or S100, an
astrocyte marker, and pS6. In the rostral cerebral cortex, almost all
NeuN-positive cells in the mutant demonstrated increased pS6 antigen
(Fig 3.2F,G). Similarly, the S100-positive astrocytes in the rostral cortex
of mutant mice were larger and expressed more pS6 than those of
control animals (Fig 3.2H,I). (115)

Loss of Tsc2 in radial glia causes hippocampal organizational defects and neuronal
hypertrophy in Tsc2flox/ko;hGFAP-Cre mice
Coronal sections of the mutant hippocampus revealed organizational defects of the
pyramidal layer. Defects in lamination were most severe in the CA1 and CA3 regions (Fig
3.3B, F), in which the usually well-ordered and densely-packed neuronal layer, as seen in
the control (Fig 3.3A, E), was disrupted. In fact, as most evident in the CA1 region (Fig. 3B),
the ectopic, often enlarged (Fig 3.3G, black arrowhead) neurons seemed to form an almost
distinct separate layer in the stratum oriens (SO). Though the defects in organization were
less severe in the dentate gyrus (DG) of the mutant hippocampus (Fig 3.3C, D), many
enlarged granule cells seemed to line the structure. A number of spherically-organized
ectopic cells (seen as ring heterotopias) also dominated the stratum lacunosum molecular
(SLM) of the mutant hippocampus (Fig 3.3H). Though these ring heterotopias mainly
consisted of post-mitotic NeuN-labeled neurons with a few S100-labeled astrocytes (Fig
3.3I, J, white arrowheads), some cells were present that did not stain for either marker
(black arrowhead). These NeuN-/S100- cells may represent Tsc2 null cells in which the
process of differentiating into a neuronal or glial cell may have been disrupted.
Increased activation of the mTORC1 pathway was demonstrated by greater pS6
expression in both NeuN-labeled neurons (Fig 3.3K, L) and S100-labeled astrocytes (Fig
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‡Figure 3.3. Hippocampal defects and up-regulation of mTORC1 in hippocampal
neurons and astrocytes in Tsc2flox/ko;hGFAP-Cre mice. All sections were taken from P21
mice. (A and B) Severe lamination defects in the mutant mouse (B) were apparent in H&Estained sections of the hippocampus, especially in the CA1 and CA3 regions. White arrows
represent ring heterotopias that were evident throughout the SLM. (C and D) The DG was
lined with large, ectopic granule cells in the mutant (D). (E–G) Numerous ectopic neurons
(F, black arrows) and enlarged cells (G, black arrowhead) were also present in the SO of
the mutant hippocampus (F), in contrast to the tight, well-organized pyramidal layer in the
control (E). (H–J) High power magniﬁcation of a ring heterotopia demonstrated that they
were mainly composed of NeuN-positive neurons (green cells) with some S100-positive
astrocytes (I, J, red cells, white arrowheads), though some cells do not stain for either
marker (I, J, black arrowheads). (K and L) NeuN-labeled neurons in the hippocampus of
the mutant (L) displayed greater pS6 expression than the control (K). However, expression
of pS6 in the DG of both the mutant and the control is reduced compared with their
respective PL. (M) Despite low immunohistochemical pS6 expression in the mutant DG,
average cell area of cells in the DG of the mutant was signiﬁcantly larger ( ***P< 0.0005)
than the control (n = 6). (N and O) S100-labeled astrocytes in the hippocampus of the
mutant (O) had increased pS6 expression. The SLM region of the hippocampus is shown.
Scale bars, A–F, 50 µm; G–J, 10 µm; K and L, 100 µm; M, 50 µm; N and O, 20 µm.
‡Figure and legend taken from (115).
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3.3N, O) in the hippocampus. However, expression of pS6 was not noticeably increased in
the DG of the mutant hippocampus (Fig 3.3L), though previous characterization of the
hGFAP-Cre transgenic mouse using a Rosa-26 reporter confirmed Cre expression in this
structure (83, 84). As increased mTORC1 activity often results in increased cell size, we
quantitated the area of cells within the DG and found that the average area of cells in the
mutant was significantly greater (P < 0.0005) than those of the control (Fig 3.3M),
confirming upregulation of mTORC1 activity in the mutant DG despite our inability to detect
increased pS6 expression.

Developmental analysis of Tsc2flox/ko;hGFAP-Cre mice reveals
post-natal cerebral enlargement and possible migration defects.
To analyze the development of the cerebral abnormalities seen at
P21, we examined hematoxylin and eosin (H&E) stained sections from
E16.5–P15 (Fig 3.4). At E16.5, we observed no notable difference in
thickness of the developing cortex between mutant and control (data
not shown). At P0, the difference in thickness of the cerebral cortex was
also minimal, though the ventricular zone appeared thicker in the
mutant (Fig 3.4A, B). In the hippocampus, defects in organization of the
CA3 layer of the mutant were already apparent (Fig. 3.4C, D). By P5,
the difference in cortical thickness became more pronounced while the
lamination abnormalities in CA1 and CA3 and ectopic neurons in the
SO were evident. In the hippocampal fissure, there were several
ectopic clusters of cells in the mutant brains (Fig 3.4E–H). These
clusters appeared to be the site of origin of the future ring heterotopias.
By P10, the mutant cortex was noticeably thicker than control and the
ring heterotopias were becoming more obvious (Fig 3.4I–M). By P15,
the mutant brains were similar histologically to brains analyzed at P21
(Fig 3.4N–Q). (115)
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‡Figure 3.4. Post-natal developmental analysis of Tsc2flox/ko;hGFAP-Cre mice. H&Estained sections from P0 to P15. (A–D) At P0, the size of the cerebral cortex was
comparable between the control and the mutant. The ventricular zone (arrowheads)
appeared thicker in the mutant and lamination abnormalities in CA1 and CA3 (arrows) were
beginning to develop. (E–H) At P5, an increase in the cortical thickness of the mutant (F)
was more apparent. The layering abnormalities in CA3 (arrow) were more pronounced.
There were many ectopic cells in the SO of the mutant (H, white arrowheads) compared
with the control. There was also the appearance of clusters of cells in the hippocampal
ﬁssure (black arrowhead). (I –M) By P10, the cerebral cortex of the mutant had continued to
enlarge, and the layering was indistinct compared with the control. The ring heterotopias in
the SLM were evident (inset J). The corpus callosum was also noticeably thicker.
Sectioning through a heterotopia (K–M) demonstrated that they represent a nodule of
ectopic cells. (N–Q) By P15, the same abnormalities were present as those seen at
weaning. Scale bars, A, B, E–J, N, O, 100 µm; C, D, K–M, P, Q, 50 µm.
‡Figure and legend taken from (115).
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Loss of Tsc2 in radial glia disrupts cortical lamination
To gain better insight into the lamination abnormalities identified with H and E staining
in the mutant mouse, we performed immunohistochemistry using layer-specific antibodies to
visualize individual cortical layers. Cux-1, a transcription factor that is expressed almost
exclusively in the later-born neurons of Layer II-IV of the cortex (121), was used as a marker
to reveal these well-defined layers in the control. In the mutant cortex, however, Cux1labeled cells were not clearly restricted to Layers II-IV (Fig 3.5A). Although the majority of
these labeled cells were in the appropriate cortical layers, they appeared disperse, with poor
demarcation of the bottom of Layer IV. Most notably, a number of Cux1-labeled cells were
also present in the lower cortical layers, further indication of a defect in cortical migration. As
Reelin is essential for proper neuronal positioning and cortical layer formation (122), we
examined Reelin-secreting Cajal-Retzius cells at E14.5 and found no notable difference in
their numbers or Reelin expression (Fig 3.5I), suggesting the observed migration defect was
Reelin-independent. To assess whether the ectopic cells were the result of aberrant
proliferation, we quantitated the number of Cux1-labeled cells in the control and mutant and
did not find a significant difference in density of the cells (Fig 3.5D). The migration defect
was further investigated using BrdU labeling at E15.5. BrdU is a thymidine analog that is
incorporated into dividing cells during S phase (123), and is therefore widely used to
visualize proliferating cells at a given timepoint. By labeling with BrdU during neurogenesis
and examining BrdU+ cell populations at P21, we were able to determine the final
destination of cells born at E15.5 or immediately after (Fig 3.5F). Division of the cortex into
10 horizontal bins allowed us to quantitate the number of BrdU+ cells in each bin. This
analysis demonstrated that mutant mice had increased ectopic cells in the lower layers of
the cortex compared to the control, despite the similar birthdates of these labeled cells (Fig
3.5G). No significant difference was found between the total number of BrdU-labeled cells in
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the control compared to the mutant (Fig 3.5H), supporting the Cux1 findings that migration
was disrupted in these mice, with no evidence of a proliferation defect. This conclusion was
further demonstrated by quantitation of all post-mitotic cortical neurons using NeuN, which
showed no significant difference in total neuron density between the control and mutant
animals (Fig 3.5C), while staining with PCNA, a marker for proliferation, at P10 showed no
visible discrepancies between cell number (data not shown). Though we attempted to
investigate cell death using TUNEL and cleaved caspase 3 (CC3) staining in embryonic day
16.5 (E16.5) and P10 sections, few cells in either the control or mutant appeared labeled in
our hands. We therefore concluded that the lamination defect was most likely due to
aberrant, Reelin-independent migration rather than abnormal proliferation.
Antibody against FoxP2, a transcription factor expressed exclusively in Layer VI in the
mammalian neocortex (124), was used to further examine layering defects of early-born
neurons. Interestingly, FoxP2-labeled cells remained in Layer VI in the mutant animal,
though they too appeared poorly-organized and disperse within this layer (Fig 3.5B), as
previously noted with Cux1-labeled cells. Since there seemed to be fewer FoxP2-labeled
cells in the mutant cortex, we questioned whether this disperse effect was due to lower cell
numbers or a defect in migration. In fact, density of FoxP2-labeled cells was significantly
decreased (P<0.05) in the mutant cortex (Fig 3.5E), with no evidence of labeled cells
remaining in the ventricular zone (VZ), which if seen would indicate defective migration.
Taken together, the findings described above suggest that a proliferation defect is not
present in the mutant cortex, while migration of the later-born neurons is somewhat
defective. Furthermore, aberrations in cell layer populations might exist, given that fewer
FoxP2-labeled cells are found with no difference in total neuron or Cux1-labeled density,
total BrdU-labeled cell number, or evidence of cell death. Although attempts to quantitate
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‡Figure 3.5. Lamination defects in the Tsc2flox/ko;hGFAP-Cre mice. All sections and
counts conducted in P21 mice. (A and B) Cux1 (A), a Layer II –IV marker, and FoxP2 (B), a
Layer VI marker, were used to assess lamination defects (n = 6 and 4, respectively). The
Cux1-labeled cells of the control resided mostly in their designated layers, whereas the
labeled cells of the mutant were scattered throughout the cortex. FoxP2-labeled cells were
generally in Layer VI for both control and mutant. (C–E) Although density of NeuN-labeled
neurons (C) and Cux1-labeled cells (D) were not found to be signiﬁcantly different in the
cortex, there were signiﬁcantly less FoxP2-labeled cells in the mutant (E, P =0.05). (F,G)
Cells born and labeled with BrdU at E15.5 mainly settle in the upper layers of the cortex, as
seen in the control. Mutant mice display ectopic BrdU+ cells in the lower cortical layers
(white arrows). (H) Total number of BrdU-labeled cells is not significantly different between
the control and mutant. (I) Reelin staining at E14.5 demonstrates no observable difference
between control and mutant Reelin expression of Cajal-Retzius cells in the developing
brain.

‡Figure and legend modified from (115).
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neurons in the remaining Layer V using ER-81 were unsuccessful in our hands, our results
indicate that more neurons displaying Layer V markers likely exist in the mutant.

Tsc2flox/ko;hGFAP-Cre mice exhibit altered cortical neural progenitor pools with no
evidence of aberrant proliferation
Though it is well known that the mTORC1 kinase and its downstream effectors are
highly involved in proliferation (125), we found no significant difference in numbers of
NeuN-labeled neurons in the mutant cortex. TUNEL and CC3 staining at E16.5 and P10
also revealed no noticeable increase in cell death in the mutant compared to the control
(data not shown), suggesting that our equal cell numbers were not due to proliferation then
subsequent death of cells. As cell death detection requires precise timing, we decided to
instead confirm these results by investigating proliferation using BrdU pulse-labeling at
E14.5, soon after Tsc2 deletion occurs in radial glial cells. Quantitation of BrdU-labeled
cells undergoing S phase following 30 minute pulse-labeling showed no significant
difference between control and mutant animals (Fig 3.6A-C). We therefore concluded that
defects in neuronal progenitor proliferation were not present in the mutant cortex. Though
aberrant proliferation was not observed in the Tsc2flox/ko;hGFAP-Cre mouse, we wanted to
further characterize the mechanism of the lamination defect by examining developmental
formation of cortical layers. We had previously found a significant decrease in early-born
FoxP2-labeled neurons in Layer VI of the mutant compared to the control, with no evidence
that density of later-born Cux1-cells or total neuron density was different in the cortex. We
therefore hypothesized, in the absence of evidence of cell death, that there must be an
increase in Layer V neurons, and hence a defect in generation of neurons for specific
layers. We investigated this phenomenon using markers for two major populations of cells
at this mid-neurogenesis timepoint, Tbr1 and Tbr2. During radial glial cell (RGC)-mediated
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‡Figure 3.6. Cortical neural progenitor pool analysis at embryonic day E14.5. (A–C)
BrdU pulse-labeling failed to detect any signiﬁcant proliferative differences along the
ventricles of the control and mutant embryos at E14.5 (n = 6). (D–F) Signiﬁcantly more (F,
***P <0.0005) Tbr2-labeled basal progenitor cells were found in the subventricular zone of
the mutant (E) compared with the control (D) (n = 6). (G–I) The number of post-mitotic
Tbr1-labeled neurons was signiﬁcantly decreased (I,*P <0.05) in the control (G) (n = 6). (J–
L) Radial glia numbers (L), as labeled by pax6, were not found to be signiﬁcantly different
between the control and the mutant (J) (n = 4). CP, cortical plate, SVZ, subventricular zone,
VZ, ventricular zone. A, B, G and H taken at 20x magniﬁcation, D, E, J and K taken at 40x.

‡Figure and legend taken from (115).
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neurogenesis, neurons may arise directly from asymmetric division of RGCs (126) and
become post-mitotic, thereby expressing Tbr1. Alternatively, RGCs may produce basal
progenitor cells (BPCs) that express Tbr2, which in turn give rise to post-mitotic Tbr1expressing neurons (118) in a process that produces the majority of neurons in the cortex.
Since the process of neuron production via BPCs is less direct, the majority of Tbr1-labeled
neurons at E14.5 should be the direct progeny of RGCs. Interestingly, we found a
significant (P<0.05) decrease of Tbr1-labeled post-mitotic neurons at E14.5 (Fig 3.6G-I),
accompanied by a highly significant increase (P<0.0005) of Tbr2-labeled BPCs (Fig 3.6DF). This data suggests that deletion of Tsc2 in RGCs caused an imbalance in the
production of postmitotic neurons and BPCs, where instead of directly generating neurons,
a number of RGCs generated BPCs. Then again, to replenish the neuroprogenitor pool,
RGCs may also undergo symmetric divisions and generate more RGCs, which may explain
the subsequent increase in BPCs. No significant difference in pax6-labeled RGC numbers
was found, however. Taken together, this data indicates that symmetric RGC division is not
disrupted following Tsc2 deletion, though asymmetric division into neurons or BPCs is
altered. The finding of less early-born Tbr1-labeled cells in the mutant supports our results
for fewer early-born FoxP2-labeled neurons. However, the notable increase in BPCs which
generate the majority of later-born neurons does not translate into increased Cux1-labeled
cell density by P21.

Tsc2flox/ko;hGFAP-Cre mice exhibit astrogliosis
Astrogliosis, in which astroglia become “active” in response to CNS injury and disease,
is characterized by cellular hypertrophy, abnormal astrocyte proliferation, and an increase of
intermediate filament proteins such as GFAP (127). As TSC tubers and subependymal
nodules often present with astrogliosis (119, 128), we examined the Tsc2flox/ko;hGFAP-Cre
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‡Figure 3.7. Astrogliosis in the Tsc2flox/ko;hGFAP-Cre mice. (A and C) Immunostaining
of GFAP in the cortex (A) revealed substantial increase of GFAP-expressing astrocytes in
the cortex compared with the control. Intense GFAP expression was also seen in the
mutant ventricular zone of the lateral ventricle (white arrows). As quantiﬁcation of GFAP+
cells in the cortex was difﬁcult in the control, S100 (D) was used to label cortical astrocytes.
No signiﬁcant difference was found in S100+ cells between the mutant and the control. (B
and D) GFAP expression was notably higher in the mutant hippocampus where astrocytes
had larger cell bodies but shorter, thicker processes compared with the control (B).
Signiﬁcantly more GFAP-labeled cells (C) were present in the mutant hippocampus.

‡Figure and legend modified from (115).
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mutant cortex to determine whether it displayed an astrogliosis. Immunohistochemical
analysis using GFAP revealed a substantial increase in GFAP expression in the mutant
cortex, where particularly intense GFAP expression was found in the ventricular zone of the
lateral ventricle, suggestive of disrupted migration of glia (Fig 3.7A, white arrows). GFAP
expression was also increased in the mutant hippocampus (Fig 3.7B), where astrocytes
displayed signs of being “active” with enlarged cell bodies and shorter and thicker
processes. Abnormal proliferation of GFAP-expressing astrocytes was found to be
significant in the mutant hippocampus (Fig 3.7C). Since endogenous expression of GFAP in
the cortex is too low for detection, we used antibody against S100, a mature astrocyte
marker, to quantitate astrocyte numbers in the cortex. Interestingly, we did not find a
significant increase of S100-labeled cells in the cortex (Fig 3.7D), despite augmented GFAP
expression. These results indicate that astrogliosis is present in both the mutant cortex,
where it is characterized only by astrocyte activation, and the hippocampus, where it is
characterized by astrocyte activation and proliferation.

Loss of Tsc2 in radial glia results in defective myelin progression despite increased
numbers of mature oligodendrocytes
Advances in MRI imaging techniques have identified a variety of
white matter defects in the brains of TSC patients (129, 130). Diffusion
tension MRI, which detects the direction and magnitude of water
diffusion in tissues, has even identified microstructural defects in
normal-appearing white matter from TSC patients (130). Some of the
most common white matter lesions identified in the brains of TSC
patients were gliosis and hypomyelination. The neuron-specific Tsc1
mouse model demonstrated significant hypomyelination (77). (115)
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We sought to investigate defects in white matter in our mutant mice by performing
immunohistochemistry for myelin basic protein (MBP), a major component of and a common
marker for the myelin sheath. By P10, myelin within the corpus callosum is notable in both
control and mutant animals (Fig 3.8A), though several areas display only patchy expression
of MBP in the mutant. By P15, however, the control animal contains a large number of
myelinated fibers in the lower layers of the cortex, in stark contrast to the relatively sparsely
myelinated cortex of the mutant (Fig 3.8B). The myelination patterns seen at P15 were
similar to those seen in P21. By examining myelination progress at these different stages of
postnatal development, we concluded that the hypomyelination finding was not due to
demyelination but rather a defect in myelin progression in the lower cortex.
Since the production of myelin requires differentiation from oligodendrocyte progenitor cells
to mature oligodendrocytes (131, 132), we sought to explain the hypomyelination defect by
examining mature oligodendrocytes using a marker called CC1. Surprisingly, we found a
significant increase in CC1-labeled mature oligodendrocytes in the corpus callosum of the
mutant mouse compared to the control (Fig 3.7C, D, n=4, 665 cells/mm2 ± 46 versus 532
cell/mm2 ± 35, P = 0.05), while immunostaining with pS6 and CC1 revealed that a number
of oligodendrocytes also demonstrated upregulated mTORC1 activity. In spite of the
increase in oligodendrocytes, however, myelination does not progress. It is unclear whether
the increase in mature oligodendrocytes with upregulated mTORC1 activity contributed to
the hypomyelination in the mutant mice, or if the myelin defect is unrelated to the
oligodendrocytes findings.
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‡Figure 3.8. Postnatal developmental analysis of hypomyelination and
oligodendrocytes in the mutant. (A and B) Immunostaining of MBP at P10 (A) and P15
(B) demonstrated a defect in myelin formation in the mutant cortex (arrows). (C and D)
Oligodendrocyte analysis using CC1 revealed a 1.25-fold increase in CC1-labeled cells in
the mutant (n = 4, data not shown) compared with the control. Colocalization of pS6 and
CC1 (arrowheads) showed that most oligodendrocytes in the mutant had up-regulated
mTORC1 activity.

‡Figure and legend taken from (115).
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Discussion
We have generated a mouse model in which Tsc2 is conditionally ablated from radial glial
cells, which are neuroglial progenitors involved in migration that produce the majority of
neurons and glia in the cortex and hippocampus. These Tsc2flox/ko;hGFAP-Cre mutant mice
fail to gain weight by P8 and are severely runted and sick-looking by P21, subsequently
dying of seizures at a median age of P23. They develop a postnatal megalencephaly with
dilated ventricles, cell hypertrophy and lamination defects in the cortex and hippocampus,
and ring heterotopias. Immunoblots and immunohistochemistry using pS6, an indicator of
mTORC1 activation, confirm that tuberin function is lost and mTORC1 is upregulated in
most neurons and glia of the cortex and hippocampus. These mice also demonstrate
evidence of abnormal cell division of radial glia during neurogenesis, in which the early-born
neuron pool was significantly decreased while the intermediate progenitor pool was
significantly increased. Mutant mice also demonstrate an astrogliosis and defects in myelin
formation, though there is an increase in mature oligodendrocytes within the corpus
callosum. Taken together, these data demonstrate that our mouse model recapitulates
many aspects of TSC brain pathology and will be very useful in studying this disease.

Loss of heterozygosity as a mechanism of TSC neuropathology formation
TSC is considered a tumor suppressor disease in which loss of heterozygosity (LOH)
has been readily demonstrated in almost all lesions except tubers (4, 128). This has led to
questions regarding the necessity of LOH in the formation of TSC brain pathology. One of
our goals in generating this mouse using a two-hit strategy was to determine whether LOH
would result in TSC-like neuropathology. The similarity of characteristics between our
Tsc2flox/ko;hGFAP-Cre mouse and human TSC lesions demonstrate that LOH of Tsc2 can
lead to TSC-like neuropathology, lending support to the two-hit hypothesis for brain lesion
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formation. Establishment of LOH as a mechanism for TSC neuropathology formation could
be further supported by comparing the Tsc2 heterozygous littermates of our mutant mouse,
the Tsc2+/ko;hGFAP-Cre, with the mutant itself to determine if inactivation of one allele of
Tsc2 alone can generate TSC-like neuropathology. The presence of Cre in the same radial
glial cells as the mutant is necessary in this case to control for Cre as a possible variable.
Though we have not thoroughly characterized the brain of the Tsc2 heterozygote, gross
examination suggests these mice are not distinguishably different from the control.
Characterization of other Tsc2+/- mice has also yielded little observation of brain pathology
aside from an astrogliosis (72), suggesting that both alleles of Tsc2 must be inactivated to
generate the TSC-like neuropathology observed in our mutant mouse.

What causes the megalencephaly in Tsc2flox/ko;hGFAP-Cre mice?
The presence of “giant” cells is a main characteristic of TSC brain pathology, while
association with hemimegalencephaly is considered one of the aspects of TSC brain
lesions (16). We have found that enlarged cells in the cortex and dentate gyrus as well as
postnatal megalencephaly are also major features of the Tsc2flox/ko;hGFAP-Cre mouse.
Studies regarding the effects of TSC2 deletion in Drosophila (67-70) have established
increase in cell size as a major consequence of mTORC1 activation, which we have
confirmed in the cortical and hippocampal neurons and astrocytes of the Tsc2flox/ko;hGFAPCre mouse. The cause of the increased brain size, however, is less clear. Megalencephaly
is typically thought to result from one of three events: 1) an increase in cell number (133), 2)
an increase in extracellular matrix (ECM), or 3) an increase in cell size. While we did not
find a significant difference in density of post-mitotic neurons and astrocytes in the P21
cortex, on average more cells were actually present in the larger mutant cortex. Further
characterization of this possible defect must be conducted to determine whether increase in
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cell number causes the increase in brain size (see Ch 6 Discussion for details), especially
as quantitation of cells undergoing S-phase at E14.5 has provided no evidence of a defect
in proliferation in the developing mutant cortex. We have also investigated possible
contributions to brain size from proliferation of cortical interneurons, which are not produced
from radial glia and therefore do not demonstrate Cre expression (84) but, like all other cells
in the mutant body, are heterozygous for the Tsc2 deletion. Quantitation of interneuron
populations using calretinin and calbindin showed no significant increase in numbers of
these cells (data not shown). Meanwhile, closer examination of the mutant and control
cortex, as seen in Fig 3.2C-D, suggests that the mutant cells are more sparse, which may
be indicative of an increase in extracellular matrix. While we have not directly characterized
this possibility, the similar density of cells in the control versus mutant indicates a
proportional increase of ECM with increase in cell number, suggesting a combination of the
two defects may be occurring in the mutant. In addition, we have previously shown that the
percentage of increase in neuronal cell area is similar to the percentage of increase in
cortical thickness. While more thorough investigation of all possible causes is needed, the
proportional increases in brain size to cell size suggest cell size may also contribute to the
megalencephaly.

Why do Tsc2flox/ko;hGFAP-Cre mice fail to thrive?
Though the brains of the mutant mice are enlarged, the mice are runted and display
a failure to thrive phenotype. While this symptom is typically caused by inadequate caloric
intake (134), we have tentatively ruled out starvation as a reason for this effect given that
milk is routinely seen in the stomachs of mutants, they have been observed suckling
beyond the time they stop gaining weight, and even in their sickened, hunched-over state
around P21, they still have observed feeding normally. Actual caloric intake must be
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measured before it may be formally ruled out as a reason for starvation. Possibilities other
than restricted caloric intake might also explain why the mice fail to gain weight even with
feeding. For example, though the mice may be feeding normally, signals converting this
intake into actual growth may have been disrupted. It is well-established that the mTORC1
pathway plays an important role in nutrient-sensing. Its major known role, as reviewed in
Chapter 1, is to integrate a number of signals derived from growth factors, energy status,
oxygen, and amino acids to set overall growth rates via cell cycle-coordinated growth and
division (135). By altering basic mTORC1 function via deletion of one of its major
regulators, we are directly disrupting a sensory pathway that is crucial for proper
development and growth. Though failure-to-thrive is not a common phenotype in TSC
patients, understanding of this side effect of Tsc2 deletion in our mutant mouse may
provide further insight into the role of Tsc2 and mTORC1 in gross development and growth.

Potential causes of the neuronal migration defect
Migration of neurons to their appropriate positions is critical for proper brain function.
In the mammalian brain, migration is a highly complicated process that involves a number
of signaling factors that are susceptible to influence from environmental and genetic factors
(136). Though TSC brain lesions are characterized by proliferation and differentiation
defects as well, di Mario (16) suggested in 2004 that TSC neuropathology should be
considered more cohesively as a neuronal migration disorder:
This is justified because in tuberous sclerosis complex, histologic
features exist that are characteristically identified in neuronal migration
disorders in general([such as] (1) abnormal number, size, and
thickness of cortical gyri; (2) heterotopic neuronal aggregates; and (3)
variable degrees of cortical cytoarchitectural disorganization and
aberrant columnar and laminar arrangement. (16)
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The severe defects in migration found in the Tsc2flox/ko;hGFAP-Cre cortex and
hippocampus model the characteristics described above. Basic H&E staining revealed
blurred cortical layering in the cortex, most obviously in the usually clearly-demarcated
marginal zone that is poorly defined in the mutant. Immunostaining with layer markers
provided further evidence of lamination defects, including a number of ectopic cells stuck in
the lower layers of the cortex despite their expression of upper-layer markers. Problems
with migration were particularly notable in the hippocampus, in which an almost entirely
separate layer of ectopic cells existed above the dispersely-organized pyramidal layer. Ring
heterotopias were common in the SLM region of the mutant hippocampus as well, which
developmental studies suggest may be formed by cells stuck along the hippocampal
fissure. This finding is interesting given that TSC2 has been found to play a critical role in
cell spreading, polarization, and migration. For example, fibroblast cells deficient in TSC2
were “impaired in their ability to spread and to alter actin cytoskeleton upon stimulation with
IGF-1 (137).” The majority of cells in the cortex and hippocampus of the mutant mouse
seem to exhibit only mild migration defects, as evidenced by the large number of Cux1 cells
present, though not well organized, in their designated layers and the formation of an at
least recognizable pyramidal layer in the hippocampus. However, a number of the defects
in the mutant seen do appear to be due to inhibited migration, suggesting that a
contributing factor to this effect may be Tsc2 deletion in these “stuck” cells that changes
their ability to reorganize the actin cytoskeleton efficiently.
On the other hand, the presence of less mobile cells may be due to inhibited
migration of their progenitor, the radial glial cell. The mouse mutant of the lissencephaly
gene, Lis1, exhibits a very similar pattern of hippocampal disorganization compared to our
mutant mouse. Studies in this mouse revealed that Lis1 RNAi blocked interkinetic nuclear
migration in radial glial cells (138). Radial glial cells migrate from the subventricular zone
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(SVZ) during S phase to the apical surface (AS) along the ventricle during M phase (139),
and studies have suggested that radial glia must reach the AS if mitosis is to occur (140). If
deletion of Tsc2 in radial glia affects Lis1 expression or a gene of similar function, the
observed “stuck” cells could conceivably be radial glia that had reached the AS and
generated similarly immobile neurons and glia. This hypothesis could also explain the semidifferentiated “giant” cells found in TSC brain lesions as immobile radial glia that had not
been able to reach the AS to differentiate.
Meanwhile, Lis1 RNAi was also found to block conversion of cells generated in the
SVZ by basal progenitor cells (BPCs) into their bipolar, migratory form (138). These cells
would be post-mitotic neurons that were unable to migrate to their proper layer, another
possible origin of the ectopic cells found in our mutant mouse. Indeed, about 38.8% of
cortical neurons were found to display aberrant polarity in the neuron-specific Tsc1 CKO
(77), suggesting an impact on Lis1 or a protein of similar function by Tsc1/2.
As the radial fiber tracts produced by radial glia are essential for proper radial
migration and columnar organization (141), the disruption of these tracts via Tsc2 deletion
alone may explain the migration defects we see in the mutant. Interestingly, however, both
the neuron- (77) and astrocyte-specific (75) TSC1 CKO mice exhibit defects in migration as
well, suggesting the aforementioned, radial-glia independent explanation may be more
likely. In the neuron-specific mouse, cortical lamination is mainly disrupted with little
disturbance in the hippocampus. In the latter, hippocampal organization is severely altered,
with no demonstration of neocortical lamination defects. Surprisingly, disorganization of the
hippocampus was not observed until 3 weeks of age in the astrocyte-specific Tsc1 CKO,
with progressive disruption occurring over the next 5 weeks. This is contrary to our
observations in the Tsc2flox/ko;hGFAP-Cre mutant, in which migration defects in the
hippocampus seem to be present from birth (Fig 3.4). Uhlmann et al. (75) suggest the
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progression of aberrant neuronal migration in the hippocampus may be closely related to
the astrogliosis they too observe in their mutant, where the increase in astrocytes
“displaces” the neurons. However, since they see regional specificity of the neuronal
migration though the astrocytosis occurs throughout the brain, they also suggest the
possibility that new neurons are being generated from the nestin-positive, immature
astrocytes which may be “progenitors.” Finally, they also discuss the important but still
poorly-understood relationship between astrocytes and neurons, and the possible ways
astrocytes may influence neuronal migration. Since our mouse model also displays a
reactive astrogliosis, exploration of these suggestions may yield interesting insight into the
contributions of astrocytes to TSC brain pathology. Further discussion of other possible
mechanisms behind the migration defect may be found in Chapter 6.

Astrogliosis and hypomyelination
Reactive astrogliosis, in which astrocytes undergo changes in molecular expression
and morphology, has been traditionally thought to occur in response to CNS injury (127).
Despite lack of direct injury, however, astrogliosis has been repeatedly observed in tubers
and subependymal nodules (119). Tsc2flox/ko;hGFAP-Cre mutant mice also demonstrate an
astrogliosis throughout the cortex and hippocampus, though proliferation of GFAP-labeled
astrocytes is only seen in the hippocampus. It is unclear what role astrogliosis plays in TSC
pathophysiology. Recent studies have indicated that astrogliosis is not an all-or-nothing
response, and in fact involves a “finely gradated continuum of progressive changes in gene
expression and cellular changes” (142). As such, mild-to-moderate forms of astrogliosis
may result in hyptertrophy of the astrocyte and its processes, while more severe forms may
involve proliferation of astroglia to initiate scar formation (142). Severity of the reaction is
therefore dependent on the severity of the insult. As the role of astroglia under normal
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conditions is to “maintain the integrity of the blood-brain barrier, provide neurotrophic
support for neurons, and contribute to neurotransmitter and extracellular ion
homeostasis((143)”, it is thought that disruption of these processes triggers astrogliosis as
a rescue mechanism. Studies have shown that ablation of reactive astrocytes significantly
increased neuronal death, exacerbated tissue degeneration, and impaired blood brain
barrier (BBB) repair (127) following injury.
Hence, the presence of moderate to severe reactive astrogliosis in our mutant mice
may indicate that deletion of Tsc2 in radial glia has resulted in enough insult that this
mechanism is triggered. Indeed, a majority of enlarged and reactive astrocytes are found
surrounding giant cells, or hypertrophic cells of mixed neuronal and astrocytic lineage, in
human tubers (119). Although we do not see giant cells in our mouse model per se,
enlarged cells and ring heterotopias are common, and may contribute to causing the
resulting astrogliosis.
We also observe a defect in myelin progression in the cortex of our mutant, despite
presence of mature oligodendrocytes and myelin presence in the corpus callosum. Though
it is unclear whether the increase in oligodendrocytes number has an effect on the
hypomyelination observed in our mouse, it is known that myelination of axons requires
proper signaling from the neuron (Sher 2008). This suggests the defect in myelin
progression may be indicative of damage to the neuronal axons (143), another trigger of
astrogliosis. However, in the neuron-specific TSC1 CKO mouse, astrogliosis is not
observed, despite neuronal hypertrophy and myelination defects (77). On the other hand,
astrogliosis with increased proliferation over time is seen in the astrocyte-specific TSC1
CKO (75), and aberrant mTORC1 activation has been demonstrated in reactive astrocytes
in TSC tubers (119). These studies indicate that the astrogliosis found in our mutant mouse
may simply be the result of Tsc2 deletion in these astrocytes, rather than a response
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mounted by the body to address insult. Further characterization of this mechanism will be
required to determine whether either process or a combination of both events lead to the
astrogliosis observed in our mutant mouse.
Understanding of the process by which the astrogliosis occurs will be particularly
interesting given that “hypertrophy of astrocytes during the process of epileptogenesis has
been observed before the development of seizures and in the absence of other pathological
change (144).” If reactive astroglia might significantly contribute to epileptic activity, as a
study by Tian et al. (145) indicates, inhibition of the astrogliosis alone may alleviate seizure
activity in our mice as well as patients. However, while the neuron-based TSC1 CKO
mouse did demonstrate seizure activity, reactive astrogliosis was not seen (77),
encouraging further investigation into the role of astrogliosis in TSC pathophysiology as well
as seizure activity.

Conclusions
In this study, we have generated and characterized a novel model of TSC brain
pathology by deleting Tsc2 in radial glial cells in the mouse. The Tsc2flox/ko;hGFAP-Cre
mouse exhibits a number of characteristics observed in TSC brain lesions and will provide
valuable insight into TSC-related defects as well as mammalian neurodevelopment. As both
neurons and astrocytes of this mouse display highly upregulated mTORC1 kinase activity,
future work will assess the effect of mTORC1 inhibitors such as rapamycin on the various
TSC-like defects discussed. These efforts will significantly increase our understanding of
TSC pathology while elucidating the roles of mTORC1 and other pathways in TSC
neuropathology formation.
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Chapter Four:
Rapamycin Treatment of the Tsc2flox/ko; hGFAP-Cre Mouse
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Introduction
The Tsc2flox/ko; hGFAP-Cre mouse recapitulates many characteristics of human TSC
neuropathology, including megalencephaly, cell hypertrophy, defects in lamination,
hypomyelination, and astrogliosis. These similarities make it an excellent model with which
to test novel therapies. As the main known role of the hamartin-tuberin TSC complex is to
inihibit the mTORC1 kinase, preclinical animal studies and human studies have been
initiated to determine whether rapamycin, a macrolide that also inhibits mTORC1, might be
able to “replace” the function of the lost TSC complex. Treatment in TSC1 CKO mouse
models indicate that rapamycin is able to decrease brain and cell size, inhibit seizures, and
alleviate myelin defects and astrogliosis (93, 94). Human studies have shown that treatment
with rapamycin results in reduction of subependymal giant cell astrocytoma (SEGA) size,
though it appears to have little impact on tubers (146). Though these studies demonstrate
substantial benefits of rapamycin use on TSC-related defects, full rescue of the
neuropathology has not been achieved. Continuous treatment with rapamycin was also
needed in both human and mouse studies to prevent resurgence of the disease state.
These preliminary findings of the effects of rapamycin on TSC neuropathology have
raised a number of considerations regarding the potential of rapamycin for the treatment of
TSC. First, the aforementioned studies all began treatment postnatally, with the earliest
mouse treatment beginning at P7 (94). As TSC is a developmental disorder, however, the
majority of defects in the brain are believed to be initiated during prenatal
neurodevelopment. Tubers have been detected as early as 19-20 weeks in a human fetus
(78, 79). Therefore, by the time rapamycin is administered postnatally, the majority of TSC
defects have already formed. We hypothesized that rapamycin rescue might be more
effective if administered during fetal and early development. We therefore designed a series
of treatment regimens that would compare and contrast prenatal, postnatal, and combined
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pre- and postnatal rapamycin treatments. The prenatally treated group was administered
rapamycin at E12.5, when Tsc2 is deleted, until birth in pregnant dams as the “prenatal” or
“pre rap” treatment cohort (Fig 4.1). We then withdrew treatment and allowed the mice to
live until P21, at which point we examined their brains for comparison to the untreated
mutant. Characterization of this cohort not only determined the extent of rapamycin’s ability
to rescue prenatal defects, but tested whether prenatal rescue can inhibit formation of
postnatal defects such as megalencephaly and hypomyelination.
Neurodevelopment continues throughout the postnatal period, as evidenced by the
several defects in the Tsc2flox/ko; hGFAP-Cre mice that developed postnatally. We therefore
hypothesized that immediate postnatal treatment might also be more effective than
treatment from P7. Though prenatal rapamycin treatment seems ideal to rescue
developmental defects, the immunosuppressive properties of rapamycin as well as its
general effect of suppressing translation and anabolic processes may limit its practicality for
similar use in a clinical setting. We therefore treated a second “postnatal” or “post rap”
cohort from P0-P21 with rapamycin to determine whether simply including neonatal
treatment may result in greater rescue than later postnatal initiation. Finally, as the role the
mTORC1 pathway plays in TSC pathology formation is not well understood, there is a
possibility that rapamycin alone may not be sufficient to rescue all TSC defects. We
explored the role of mTORC1 in TSC pathology by ensuring rapamycin presence
throughout the life of the mouse from E12.5-P21 in a “pre+post” cohort, such that alleviation
of any defects could be attributed solely to rapamycin involvement. Examination of the
effects of rapamycin in each of these cohorts allowed us to determine the potential of
rapamycin to inhibit different defects found in TSC neuropathology.
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Fig. 4.1. Rapamycin treatment cohorts. Control (Tsc2

flox/+

) and mutant (Tsc2flox/ko;

hGFAP-Cre) mice were divided into three treatment cohorts and treated intraperitoneally
(IP) daily with 0.1 mg/kg rapamycin. “Prenatal” mice were treated in utero from embryonic
day 12.5 (E12.5) to birth, at which point rapamycin was withdrawn. Resulting pups were
monitored until P21, at which point they were taken for analysis. The “postnatal” group was
treated from postnatal day 0 (P0) to weaning age at P21 and the “pre+post” cohort from
E12.5-P21; both groups were analyzed at P21.
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Materials and Methods
Mice and genotyping – See Chapter 3.

Rapamycin – Rapamycin was purchased from CalBioChem and solubilized in 100%
methanol at 1.0 mg/ml for storage at -20°C for up to two months. Immediately before use,
rapamycin was diluted with PBS and administered intraperitoneally (IP) at 0.1 mg/kg daily
with a 30G½ needle from either 1) E12.5-birth (pre rap), 2) P0-P21 (post rap), or 3) E12.5P21 (pre+post).

Histological studies – Histological studies were conducted as previously described in
Chapter 3. Staining with antibody against Cre was used to verify genotype in some cases
(data not shown).

Quantitative analysis – All analyses were conducted using a minimum of 3 control and
mutant mouse pairs per comparison, in which 3 serial sections were used per mouse
unless otherwise noted. Sections were stereotactically matched, with areas of analysis
taken at similar distances from the midline. Count results were modified to correct for
differences in total cortical size. For Cux1 analysis, all Cux1-labeled cells that spanned the
thickness of the somatosensory cortex were counted. A line was then drawn to differentiate
between Layers II-IV and Layers V-VI, with cells falling into the latter layers considered
“ectopic.” Likewise, for assessment of hippocampal organization, a line was drawn between
the organized pyramidal layer and the cells above it, with the latter being considered
“ectopic”. For cell size analysis, sections were double-labeled with Cux1 and NeuN. Only
cells that demonstrated colocalization of both markers in Layers II-IV were used for area
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counting, to control for intrinsic differences in cell size between these and lower layers.
Data was analyzed using a repeated-measures ANOVA in Microsoft Excel (Seattle, WA).

Immunoblotting – Mice were anaesthetized with 2.5% avertin in dH2O before
decapitation. Heads were immediately submerged in ice-cold artificial CSF (in mM: 10
HEPES, pH 7.2, 1.3 NaH2PO4.H2O, 3 KCl, 10 glucose, 26 NaHCO3, 2 MgCl2.6H2O, 124
NaCl) containing phosphatase inhibitors (2 NaF, 2 Na Molybdate, 1 Na Orthovanadate) until
brain was extracted, quick-frozen in a dry ice/ethanol bath, and stored at -80°C until use.
Cortex and hippocampus samples were homogenized on ice in 10x volume artificial CSF
with 1% each of phosphatase inhibitor cocktails 1 and 2 and 1% mammalian protease
inhibitor cocktail (Sigma) in a glass dounce homogenizer. Samples were sonicated on ice
and centrifuged at 13,000 x g at 4°C for 10 min. Supernatant was isolated for protein
concentration determination using a BCA reagent kit (Pierce, ThermoFisher Scientific,
Rockford, IL). Samples were loaded on a 4-12% Bis-Tris gradient gel (Invitrogen) and
transferred onto PVDF membrane. The membrane was blocked with 5% BSA in TBST for 1
hr at room temperature, cut into sections, and probed with primary antibody in 5% BSA in
TBST for 3 hours at room temperature or overnight at 4°C. Horseradish peroxidaseconjugated secondary antibody was then applied for 1 hr at room temperature. Protein was
visualized using an ECL reagent (Amersham) prior to exposure to X-ray film (CL-X Posure,
Thermo). Blots were stripped using Restore Plus Western Blot Stripping Buffer for 15
minutes (Thermo) as necessary.

Antibodies – For immunohistochemistry, antibodies used were: Cux1 (1:50, Santa Cruz),
GFAP (1:400, Sigma), NeuN (1:100) and MBP (1:200) (Millipore). Antibodies used for
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immunoblotting were: tuberin (1:500), hamartin (1:500), S6 (1:500), and pS6 (S235/236)
(1:500) from Cell Signaling.

Results
Low dosage of rapamycin is sufficient to attenuate mTORC1 activation in mutant
mice to near-control levels
Zeng et al. (93) determined that 3.0 mg/kg of rapamycin was sufficient to “almost
completely” inhibit activation of the mTORC1 pathway in control murine cortex, as
demonstrated by phosphorylated S6 (pS6) expression in cortical lysates. A dosage of 1.0
mg/kg, however, was only able to decrease pS6 expression to about 75% of control level.
Prior to conducting the pre- and postnatal rapamycin experiments, we optimized a
rapamycin dosage that would not inhibit essential growth and development.
We began with a daily dose of 2.0 mg/kg starting at P0, which proved to be too high as
all treated animals were runted compared to vehicle-treated control by P21 (data not
shown). We therefore tested lower dosages (1.5, 1.0, and 0.5 mg/kg) using the same
treatment scheme and found similar problems with growth inhibition. Our final test using a
dosage of 0.1 mg/kg, however, resulted in healthy control and mutant mice that were both
largely indistinguishable from vehicle controls. Lysates of the cortex and hippocampus of
mutant and control animals treated with 0.1 mg/kg rapamycin demonstrated that this
dosage was able to decrease mTORC1 activity in mutants to near-control levels as
determined by pS6 expression (Fig. 4.2). Though other in vivo mouse studies have used as
much as 3.0 - 6.0 mg/kg for their rapamycin dosages (93, 94), the reduction of pS6 to wild
type levels suggest that 0.1 mg/kg would effectively inhibit mTORC1 activity when
administered between P0 and P21.
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Fig 4.2. Postnatal rapamycin dosage of 0.1 mg/kg attenuates mTORC1 expression.
Western analysis was conducted using cortical and hippocampal lysates from P21 control
and mutant mice that were either untreated or treated daily with 0.1 mg/kg rapamycin.
Minimal tuberin expression is seen in all mutant samples, while hamartin is present in both
control and mutant. Expression of phosphorylated S6 (pS6), a readout of mTORC1
activation, is increased in the cortex and hippocampus of the untreated mutant but is
reduced in the mutant following rapamycin treatment. Activity of mTORC1 is also
attenuated in control animals following treatment with rapamycin. Total S6 is used as a
loading control.
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Rapamycin treatment improves health, promotes weight gain, and extends lifespan
As previously reported (115), Tsc2flox/ko; hGFAP-Cre mutant mice displayed a failure to
thrive phenotype beginning P8, such that they were severely runted and sick-looking by
weaning (Fig 4.3A). Following prenatal treatment with rapamycin, mutant mice achieved
similar weights as their treated littermate controls until about P14 (Fig 4.3E), when their
weight gain began to slow. By P21, these mice also appeared runted compared to controls,
though to a lesser degree than the untreated mutant at the same timepoint (Fig 4.3B). In
contrast, post rap and pre+post mutant mice were virtually indistinguishable from their
littermate controls by weight or overall health throughout postnatal development (Fig 4.3C,
D).
In addition to improving weight gain and health, rapamycin was also able to extend
lifespan for all three treatment cohorts. Discontinuation of rapamycin, however, invariably
resulted in seizures and subsequent death (Fig 4.3F). While the untreated Tsc2flox/ko;
hGFAP-Cre died at a median age of 23 days, the pre rap mutant lived until a median age of
P31. Meanwhile, the post rap and pre+post mutants, whose treatments ended at P21, lived
until P45 and P41, respectively. Following withdrawal of rapamycin, the latter two groups
initially exhibited comparable weight gain to their littermate controls, though this gradually
slowed and reversed within two weeks (data not shown). In their last week of life, several
mice from these two groups were observed seizing before dying days later of seizures.
Previous studies in our lab conducted using 2.0 mg/kg of rapamycin (administered from
P10, 3x/week) showed that rapamycin was able to extend lifespan and maintain health until
P150, when the study was discontinued (data not shown).
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Fig 4.3. Comparison of rapamycin treatment cohorts. (A) By P21, the untreated mutant
mouse is sick and runted compared to its littermate control. (B) Mutant mice are still smaller
than controls following prenatal rapamycin treatment, though they appear healthier and
larger than their untreated counterparts. (C, D) Postnatal and pre+post treatment results in
mutant mice that are clinically indistinguishable from their littermate controls. (E) Weights of
all four cohorts demonstrate that rapamycin does not have a noticeably negative effect on
weight gain in control mice. Untreated mutants demonstrate a failure to thrive phenotype
beginning P8. Pre rap mutants have similar weights as the control until around P14, at
which point their weight gain plateaus. Post rap and pre+post mutants are similar in weight
compared to controls. (F) Mutants of all cohorts die of seizures following withdrawal of
rapamycin, denoted by the X. The median age of death for each cohort is: untreated, P23
(n=20); pre rap, P31 (n=12); post rap, P45 (n=6); pre+post, P41. (n=5).
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Rapamycin alleviates megalencephaly and cell hypertrophy in the cortex
We examined the effect of rapamycin on cortical thickness and cell size using H&Estained sections of each treatment cohort. In untreated Tsc2flox/ko; hGFAP-Cre mutant mice,
we previously demonstrated a postnatal cerebral enlargement that resulted in a significantly
thicker cortex than control mice by P21 (115) (Fig 4.4A). Interestingly, pre, post, and
pre+post treatments all reduced cortical thickness to near-control levels (Fig 4.4B-D).
Though the size of the control cortices were also decreased with each of these rapamycin
treatments compared to the untreated control, the difference was not found to be significant
(Fig 4.4I).
Neuronal hypertrophy was also demonstrated in the cortex of the untreated mutant.
This was originally shown by comparing the average area of cells labeled with NeuN, a
post-mitotic neuronal marker, in the mid-fifth section of mutant versus control cortices. To
ensure that intrinsic differences between size of cells in Layers II-IV and Layer V did not
influence our comparisons, we chose to calculate cell area of layer-specific cells by
analyzing cells co-labeled with NeuN and Cux1, a Layer II-IV marker. Using this method of
assessment, cortical neurons of the untreated mutant were still found to be significantly
larger compared to the control (Fig 4.4E). However, following rapamycin treatment (Fig
4.4F-H), cell size was found to be significantly reduced in the mutant brains (Fig 4.4J). As
mTORC1 is a known regulator of cell size, this finding served to validate the effectiveness
of rapamycin treatment in these mice.

Combined pre+postnatal rapamycin treatment rescues lamination defects in mutant
cortex
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Defects in lamination were observed in the untreated mutant cortex, with noticeable
blurring between the usually well-defined cortical layers (Fig 4.4A). This abnormality was
particularly apparent in the marginal zone, the normally clearly-demarcated, cell-sparse
layer adjacent to the pial surface, which is poorly delineated in the mutant (Fig 4.4A, white
arrows). Postnatal treatment with rapamycin alone did not notably improve the definition of
this layer, while prenatal treatment appeared to result in slight improvement of this defect.
The combined pre+post treatment, however, resulted in a considerable degree of rescue,
with a marginal zone similar to that of the untreated control (Fig 4.4D, yellow arrow). We
investigated cortical lamination more closely using antibody against the transcription factor
Cux1 to identify neurons of Layers II-IV (38). We had previously shown an excess of Cux1labeled cells in cortical layers V and VI of the mutant animals, suggesting a defect in
neuronal migration (115) (Fig 4.5A). Quantitative analysis of rapamycin-treated samples
(Fig 4.5E) demonstrated that treatment with rapamycin prenatally resulted in a significant
reduction of ectopic cells in the lower layers, whereas postnatal treatment alone showed no
significant impact on ectopic cell number (Fig 4.5B-D). Mutant mice treated pre+postnatally
therefore also demonstrated a significant degree of rescue in the number of ectopic Cux1labeled cells in the cortex. These data suggest that rapamycin is able to rescue cortical
migration defects that occur postnatal.

Combined pre+postnatal rapamycin treatment rescues lamination defects in mutant
hippocampus
One of the most striking defects in the untreated mutant was found in the
hippocampus, in which the usually tightly-organized pyramidal layer was severely disrupted,
particularly in the CA1 and CA3 regions. Interestingly, ectopic cells in the CA1 region were
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Fig 4.4. Rapamycin reduces cortical thickness, cell size, and alleviates lamination defects. (A) H&E analysis of cortical sections at P21 reveal
that untreated Tsc2flox/ko; hGFAP-Cre mice have significantly thicker cortices compared to control and an ill-defined marginal zone (white
arrows). (B-D) Following rapamycin treatment, all three cohorts demonstrate a reduction of cortical thickness in the mutant, while the
pre+post mutant also shows a well-demarcated marginal zone (yellow arrow). (E) Higher magnification of the cortices reveal enlarged,
dysplastic cells in the mutant. (F-H) This enlargement is rescued by treatment with rapamycin. (I) Rapamycin treatment reduces cortical
thickness in all three mutant cohorts to levels similar to the untreated control. (J) Cell area is also significantly reduced following rapamycin
treatment.

not only enlarged but seemed to form a distinct layer above the hippocampus, suggesting a
severe defect in lamination (115) (Fig 4.6A). Pre- or postnatal-only treatment with
rapamycin did not appear to have a notable impact on this effect. The cortex of pre+post
mice, however, showed a marked decrease in ectopic cells above the pyramidal layer of the
hippocampus. Using NeuN-stained sections (Fig 4.6B), we quantitated the number of
ectopic neurons in each cohort and found a significant reduction in the pre+post treated
cohort compared to the untreated mutant (Fig 4.6C). These results indicate that the
migration defect in these ectopic cells cannot be rescued by pre or postnatal rapamycin
application alone, but requires continuous rapamycin presence.
We previously noted in Chapter 3 (Fig 3.4) the presence of a number of ring
heterotopias in the SLM region of the mutant hippocampus by P10, which may have been
formed from cells unable to migrate from the hippocampal fissure of the SO as shown by
P5. Interestingly, no heterotopias were found in animals treated prenatally with rapamycin
(n=5) or the combined pre+post treatment (n = 8). Postnatal treatment with rapamycin,
however, still resulted in ring heterotopia formation (n = 7). Contrary to the conclusions
above, these results suggest that prenatal rapamycin alone is able to alleviate the delayed
migration of these ectopic cells, which cannot be rectified by postnatal treatment.

Postnatal rapamycin treatment rescues myelination defect and astrogliosis
We found an impairment of myelin progression in Tsc2flox/ko; hGFAP-Cre mutant mice,
where myelin was present in the corpus callosum yet largely absent in the cortex (115) (Fig
4.7A). We examined the effects of rapamycin on this defect using antibody against myelin
basic protein (MBP) in P21 brain sections from each treatment cohort. Rapamycin
treatment was effective in rescuing the myelination defect when given postnatally, as both
post- and pre+post treated groups displayed an abundance of myelinated fibers in the lower
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Fig 4.5. Prenatal rapamycin treatment alleviates cortical layer defect. (A) Untreated
mutant sections stained for the cortical layer II-IV marker Cux1 demonstrated lamination
defects, with significant numbers of ectopic cells in the lower layers as quantitated in (E).
(B) Prenatal treatment with rapamycin rescues this migration defect, as significantly fewer
ectopic cells are found in Layers V-VI (**p<0.005). (C) Postnatal treatment did not appear to
have an effect this migration defect, as they had similar numbers of Cux1 ectopic cells
compared to the control. (D) The pre+post treatment demonstrated an even greater degree
of rescue than that of the prenatally treated mouse (***P<0.0005). (E) Quantitation of
Cux1+ ectopic cells in layers V-VI of the cortex.
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cortex (Fig 4.7C, D). When given only prenatally, however, rapamycin did not appear to
increase progression of myelin to the cortex (Fig 4.7B), confirming myelination as a
postnatal process. Mutant mice were also found to exhibit an astrogliosis in both cortex
and hippocampus, in which GFAP expression was strongly increased (Fig 4.7E). Similar to
our findings regarding myelin, postnatal rapamycin was able to rescue the astrogliosis,
while prenatal treatment alone resulted in an astrogliosis similar to that seen in the
untreated mutant (Fig 4.6F,G). Combined pre+post treatment also resulted in prevention of
the astrogliosis (Fig 4.6H), establishing the astrogliosis as a postnatal effect as well.

Discussion
With the establishment of the Tsc2flox/ko; hGFAP-Cre mouse as a good model for
TSC neuropathology (Chapter 3), we have chosen to use this mouse to explore the efficacy
of rapamycin treatment in alleviating TSC defects. As TSC is largely a developmental
disease, we sought to determine whether in utero treatment with rapamycin would be more
effective in rescuing neurodevelopmental defects. However, as development does occur
throughout the postnatal period, we also wanted to determine whether immediate
rapamycin treatment might be more effective than later postnatal administration. We hence
chose to systematically investigate these hypotheses by dividing our rapamycin treatments
into three separate cohorts – pre rap, post rap, or pre+post.
Though we initially began with a rapamycin dosage of 2.0 mg/kg, we found that this
amount runted wild type mice when administered postnatally. Following a dosage
determination study, we lowered our dosage to 0.1 mg/kg, which not only had minimal
clinical effect on wild type mice but also restored the ability of the mutant mice to gain
weight. Analysis of postnatally treated brains showed that this dosage was enough to
decrease pS6 expression, a readout of mTORC1 activation, to control levels. The impact of
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Fig 4.6. Pre+postnatal rapamycin treatment rescues lamination defects in the
mutant. (A) H&E-stained sections of mutant mice of each treatment cohort demonstrate
different degrees of lamination rescue, particularly notable in the pre+post treated mutant.
(B) NeuN-stained sections were used to quantify lamination rescue by quantitating the
number of ectopic cells above the pyramidal layer of the hippocampus. (C) Quantitation
demonstrates that there are significantly fewer ectopic cells in the pre+post treated mutant
compared to the untreated mutant (***P<0.0005) and both pre and postnatally treated
mutants (**P<0.005).
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this dosage is particularly interesting from a clinical perspective. Rapamycin is an FDAapproved immunosuppressant that is administered to transplant patients to achieve serum
levels of 2-20 ng/ml (94), which translates to a maximum of 0.017 mg/kg in a 60 kg adult.
Case studies using rapamycin in TSC patients at these levels have shown that rapamycin
causes regression of SEGAs, though little effect on tubers is noted (146). Though studies in
mouse models (93, 94) have demonstrated benefits of rapamycin treatment on defects
characteristic of tubers such as cell size, they achieved this using dosages ranging from 3-6
mg/kg, several hundredfold of that given to humans. Though mouse and human
pharmacokinetics differ, we were excited to establish in this study that a more patientappropriate dosage of 0.1 mg/kg was still able to attenuate mTORC1 and rescue many
TSC defects found in tubers. Given the wide range of side effects from rapamycin use, we
felt it was important to determine that a lower dosage could result in similar clinical benefits.
However, rapamycin serum levels in these mice will need to be examined to determine
whether the mouse 0.1 mg/kg treatment is comparable to a similar dosage in humans.
We administered and withdrew rapamycin at different timepoints to elucidate effects of
individual defects on overall health and survival of the mice. Interestingly, two
characteristics were similarly altered among all treatments, cortical thickness and cell size.
As noted in Chapter 3, megalencephaly is typically caused by abnormal proliferation of
cells. However, we found no evidence of increased density of neurons, astrocytes, or
interneurons in the untreated cortex of the mutant mouse, despite the seemingly sparser
distribution of cells which suggested an increase in extracellular matrix. These results led
us to conclude that the increase in cell size contributed significantly to the proportional
increase in cortical size. Following rapamycin treatment, cortical thickness was decreased
to control levels in all three treatment cohorts, while neuronal cell size significantly
decreased as well. These results lend further support to our conclusion that increased cell
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Fig 4.7. Postnatal rapamycin rescues myelin defect and astrogliosis. (A) Immunostaining with myelin basic protein (MBP) demonstrated a
marked reduction of myelin the lower cortex. MBP staining was present though patchy in the corpus callosum, suggesting a problem with
myelin progression rather than formation. (B) Prenatal mutant mice exhibited similar myelination defects as the untreated mutants. (C, D)
Postnatal treatment with rapamycin appears to fully rescue this defect. (F) Examination of astrocyte activity using GFAP reveals a notable
increase in GFAP expression, indicative of an astrogliosis. (G) High expression of GFAP is still present despite prenatal treatment with
rapamycin. (H, I) Postnatal treatment decreases GFAP expression to control levels.

size is a major factor in the development of megalencephaly.
However, though density of cells, a measure of total cell number divided by total
cortex area, did not differ in the untreated control versus mutant, total cell counts were
higher in the latter. As the mTORC1 pathway is important for translation, cell cycle, and
microtubule dynamics (147), attenuation of this pathway via rapamycin provides a good
opportunity to determine whether increased cell size does explain the cortical thickness in
our mutant. This may be done by assessing whether total neuron and astrocyte counts for
the rapamycin-treated mice differ compared to each other and the untreated mutant. For
example, the rapamycin-treated mutants might have similar total cell populations as the
untreated mutants and therefore have higher cell density, despite similar cell and cortical
size as the untreated control. This result would suggest that the cortical thickness defect is
unrelated to cellular hypertrophy, and that a proliferation defect did exist in the untreated
mutant.
In addition, as overactivation of mTORC1 has been well-established to increase cell
size (57), it is interesting that cell size seems uniformly decreased across all treated
samples by P21. One would speculate that once rapamycin is withdrawn at birth in the
prenatally treated mutant cortex, mTORC1 would be allowed to function uninhibited until
sacrifice of these mice at P21. Despite the three week interval, however, prenatally treated
mice do not have enlarged cells. In fact, closer examination of these cortical cells indicates
that they are smaller than the untreated control and post or pre+post treated mutants.
Some cells even appear pyknotic. As studies have shown that rapamycin may trigger
apoptosis in some cell systems (91, 148-150) it is important to investigate cell death in our
rapamycin-treated samples. It would also be informative to determine whether prenatal
rapamycin may damage the inherent function of mTORC1 to increase cell size, or perhaps
inhibit the ability of the cell itself to grow. On the other hand, characterization of the neuron-
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specific TSC1 CKO mouse (94) showed that the benefits of rapamycin persist for several
weeks following withdrawal of treatment. If this is the case, then perhaps increase in cell
size could not occur within the short timeframe given before these mice were taken for
study.
The persistence of rapamycin benefit for several weeks after withdrawal of treatment
may explain the discrepancies between weight gain in the untreated versus treated cohorts.
The post and pre+post mutants exhibited weight gain comparable to the littermate controls,
as rapamycin was given throughout their postnatal life. Prenatally treated mice exhibited
similar weight gain until around P14, when their weight plateaued. Though they also
appeared somewhat runted by P21, they weighed more and looked more developed than
untreated mutant mice. To better establish the relationship between weight gain benefits
and rapamycin, observations of the postnatal health of prenatally-treated mice should be
compared to rapamycin serum levels of corresponding days. In addition to possibly
benefiting metabolism pathways, treatment with rapamycin may also be inhibiting seizure
activity, resulting in more normal feeding and weight gain. As we have not investigated
whether untreated and/or treated mice have subclinical seizures, data from EEG recordings
of these mice might also be compared to rapamycin serum levels to determine whether
there is a relationship between weight gain and seizure activity. These studies would also
demonstrate how long benefits of rapamycin persist despite lowered serum levels following
withdrawal of treatment. These results will contribute greatly to our knowledge regarding the
role of mTORC1 in growth and development.
We found defects in myelin progression and an astrogliosis in the untreated mutant,
which were still apparent in the prenatally-treated mutant. Postnatally administered
rapamycin, however, rescued both of these defects, with wildtype-like progression of myelin
fibers in the lower cortex and minimal evidence of astrogliosis in both post and pre+post
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cohorts. In Chapter 3, I discussed the possibility that the hypomyelination observed was
due to a reason independent of problems with the oligodendrocytes, such as axonal
damage of the neurons in the lower cortex. This was in part based on findings in the
neuron-specific TSC1 CKO in which hypomyelination was observed despite lack of Cre
expression or differences in populations of the oligodendroglia (77). The lack of rescue in
the prenatally-treated mice suggest that either (a) prenatal rapamycin was unable to rescue
defective events that later resulted in hypomyelination, such as oligodendrocytes formation
and subsequent maturation, (b) overexpression of mTORC1 following effective prenatal
treatment is still sufficient to inhibit proper myelination, or (c) the defect in myelination in our
mouse is due to a predominately postnatal effect , such as dendritic arborization and
synapse formation of more newly-born neurons. More in-depth characterization of the
myelin defect itself, such as myelin-thickness assessment, as well as investigation of
axonal health and formation is necessary before further conclusions may be made. As
astrogliosis was also not observed in the neuron-specific Tsc1 CKO (77) but was in the
astrocyte-specific Tsc1 CKO (75), I also hypothesized that the astrogliosis in our mutant
may not have been in response to axonal damage and was instead due to increased
mTORC1 activity in the astroglia. The ability of rapamycin to inhibit the astrogliosis hence is
logical.
One of the most striking defects found in the untreated Tsc2flox/ko; hGFAP-Cre mutant
involved aberrant lamination. Demarcation of the cortical layers and organization of the
hippocampus were largely disrupted, and a number of ectopic cells stained with the upper
layer marker Cux1 were found in lower layers. We also found a number of ring heterotopias
within the hippocampus, possible indicators of abnormal neuronal migration. As migration
occurs early in neurodevelopment (141) and studies suggest mTORC1 is highly involved in
this process (137, 151), we hypothesized that prenatal rapamycin treatment would alleviate
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most lamination defects compared to post or untreated. As expected, heterotopias were
present in the post treated mutants and absent in the pre treated cohort. Fewer Cux1+
ectopic cells were also found in the pre versus post mutants, while the post and untreated
groups exhibited similar numbers. However, no significant difference was found in the
number of NeuN+ ectopic cells above the hippocampus between the untreated, pre, or post
mutants. These results suggest that the timing and mechanisms of migration, as well as the
involvement of mTORC1 in these mechanisms, may differ in different regions of the brain.
However, combined pre+post treatment resulted in almost full laminar rescue in the
cortex and the hippocampus, resulting in a clearly demarcated Layer I of the cortex,
significantly fewer Cux1 cells compared to the post or untreated mutants, and significantly
fewer NeuN+ ectopic cells above the hippocampus than pre, post, or untreated mutants.
Indeed, the pre+postnatally treated mutant is histologically similar to untreated control
brains . These results indicate that mTORC1 activity is highly involved in neuronal
migration, and tight regulation of its activity is needed both pre- and postnatally to ensure
proper cellular migration. This may be further established by examination of prenatallytreated mutants at P0, which should show wildtype-like organization if this is the case.
Despite the high degree of rescue in the pre+post treated mutant, once taken off
rapamycin, these mice only live an additional 4 weeks before they die of seizures, like the
pre and post-treated mutants. We have not examined the brains of these mice following
withdrawal of rapamycin. In their neuron-specific TSC1 CKO mouse, Meikle et al (94) found
that mTORC1 was upregulated and cell size increased following removal of rapamycin,
though rescued myelination did not regress. It is likely that we would find similar results in
our treated mouse, though cell size might not increase in the prenatally treated mouse for
reasons previously discussed. However, these studies make clear that despite seemingly
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full histologic rescue, as seen in the pre+post mice, the presence of rapamycin must be
constant to prevent recurrence of lesion formation.
By treating the Tsc2flox/ko; hGFAP-Cre mice with rapamycin at different timepoints, we
have been able to elucidate the impact of rapamycin on several prominent defects in TSC
neuropathology. Pre, post, and pre+post treatments all restore cortical thickness and cell
size to control levels. Postnatal treatment is able to rescue the hypomyelination and
astrogliosis, while prenatal treatment seems to be more beneficial in rescuing some
migrational defects. However, our studies show that correct migration in our mouse requires
proper pre- and postnatal signaling, as a combination of pre+post treatment appears to
more completely rescue migrational defects in both the cortex and hippocampus to a much
greater degree than prenatal treatment alone. While further characterization is needed to
fully understand the impact of the different treatments on TSC neuropathology, the
astounding degree of rescue following pre+post treatment suggests that this combined
treatment may provide the greatest benefit to patients in inhibiting TSC lesion formation.
However, as histologic improvement does not always translate to functional improvement,
we explored the degree of functional benefit the combined pre+postnatal rapamycin
treatment has on the Tsc2flox/ko; hGFAP-Cre mice in the following chapter.
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Chapter Five:
Behavioral Testing of Rapamycin-Treated Tsc2flox/ko; hGFAP-Cre Mice
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Introduction
More than 95% of TSC patients exhibit brain manifestations, which have been
associated with a wide range of neurologic morbidity such as mental retardation, behavioral
problems, and learning difficulties (152). Even the approximately 50% of TSC patients who
have a normal IQ of 80-130 are often affected with neuropsychological deficits (153), which
include deficits in long-term and working memory (154, 155). Indeed, recent studies in
mouse models have demonstrated that haploinsufficiency of either Tsc1 (156) or Tsc2
(157) result in impaired learning and memory, despite absence of cerebral lesions or
seizures.
These findings underscore the importance of the TSC genes in learning and memory,
which are thought to stem from their regulation of the mTORC1 pathway. Long-term
learning and memory require the synthesis of new proteins, a process that mTORC1 tightly
regulates in response to nutrients and growth factors (158). Stimulation of late long-term
potentiation (L-LTP), used to measure memory at a cellular level, results in phosphorylation
of mTORC1 downstream effectors such as 4E-BP1 and S6K1 (159). Studies in wild type
rats both in vitro (160) and in vivo (161) have also demonstrated that inhibition of the
mTORC1 kinase using rapamycin in the hippocampus results in impaired long term
memory, providing further evidence of the importance of this pathway in learning and
memory.
As established in Chapter 3, the Tsc2flox/ko; hGFAP-Cre mouse models many
characteristics of TSC neuropathology. Given this and the prevalence of learning and
memory deficits in the TSC population, we hypothesized that our mutant mouse could be
used to better understand these cognitive deficits. Unfortunately, the severity of defects in
the untreated mutant results in sickness and death by P23, too young an age for most
behavioral tests. As described in Chapter 4, however, a combination of pre+postnatal
93

rapamycin treatment in these mutants demonstrated nearly complete rescue of these
defects, including weight gain, cortical thickness, cell size, cortical lamination, myelin
progression, and an astrogliosis. Most striking, however, was the restoration of organization
to the hippocampus, which appeared nearly indistinguishable from controls when analyzed
with H&E and NeuN immunohistochemistry. This finding was particularly relevant given the
importance of the hippocampus in long term learning and memory. As this treatment
scheme seemed to restore the majority of histological defects we noted, particularly those
in the hippocampus, we sought to assess whether the histologic rescue correlated with
functional rescue of cognition and behavior. Control and mutant animals that had been
treated with rapamycin were assessed with a battery of behavioral tests measuring learning
and memory.
Since untreated mutants could not be used for comparison, we chose instead to test
the postnatally-treated rapamycin cohort, which showed a lesser degree of histological
rescue compared to the pre+post group. Comparisons of control and mutant mice of these
two groups demonstrated not only whether histologic rescue translates to functional rescue,
but whether combined pre+postnatal treatment with rapamycin improved learning and
memory in this mouse model to a greater degree than postnatal treatment alone.

Materials and Methods
Mice – As described in Chapter 4, Tsc2flox/ko; hGFAP-Cre (mutant) and Tsc2flox/+ (control)
mice used for behavioral testing were treated with rapamycin either from birth (postnatal
day 0, P0) (“postnatal treatment”) or beginning embryonic day 12.5 (E12.5) until adulthood
(“pre+post treatment”). All mice were treated with rapamycin throughout behavioral testing,
which began on average around P48. Control and mutant mice from both treatment cohorts
were given coded IDs and randomly segregated into new groups for all behavioral testing,
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which was done in collaboration with Natalia Rozas, a doctoral student in the laboratory of
Pramod Dash, Ph.D. All testing and mouse handling was approved by the UT Animal
Welfare Committee.

Rapamycin – Rapamycin preparation was the same as that described in Chapter 4.
Briefly, rapamycin was solubilized in 100% methanol and stored at a concentration of 1.0
mg/mL at -20°C for up to two months. Rapamycin was diluted with PBS immediately before
use and administered IP at a dosage of 0.1 mg/kg daily with a 30G½ needle until P30-45 in
both post rap and pre+post groups. Around this timepoint, mutant mice from both cohorts
began to look sick, with one prenatally-treated and one pre+post treated mutant dying of
seizures. This was likely due to decreased permeability of rapamycin through the blood
brain barrier as mice aged, as studies have demonstrated decreased rapamycin
concentration in the brain beyond P30 (Meikle 2008). Since previous experiments had
shown that a dosage of 2 mg/kg administered three times a week was sufficient to extend
lifespan and maintain health, all mice were switched to this treatment scheme at least one
and a half weeks before behavioral testing began. Treatment continued at this dosage
throughout behavioral testing.

Motor skills – To assess motor coordination, mice were tested on a Basile automated
accelerating rotarod using a protocol set forth by Crawley and Paylor (162). Mice were
trained for 90s at a constant 16 rpm before being tested for 300s at an accelerating 4-40
rpm. Mice were then allowed to rest in their home cages for 2 hours before being tested
again for 300s at 4-40 rpm. Latency to fall for all trials was recorded.
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Morris Water Maze – Spatial learning and memory was assessed using a standard
version of the Morris water maze. Briefly, a tank (1.2 meters in diameter) located in a dimlylit testing room was filled with water mixed with non-toxic white paint, rendering it opaque. A
circular platform (11 cm in diameter) was submerged 2 cm below the surface of the water.
Spatial cues, including lights as well as brightly colored shapes, were stationed on the walls
around the tub. Before each trial, mice were taken from their home cage and individually
placed in clean, diaper-lined cages with a heated water bottle for warmth. After 10 minutes
of habituation, the trial began by placing a mouse into the tub from a random start location.
Each mouse was given 60 s to locate the platform. If it could not within the 60 s, the blinded
experimenter would guide it towards the platform and let it sit for 10 s. The mouse was then
taken back to its bottle-heated cage to await the next trial, with a minimum inter-trial time of
4 minutes to rest. Activity of the mouse was tracked by an overhead camera, including
swim speed, latency to platform, and swim direction.
Two variations of the Morris water maze were conducted in the order described below.
Mice initially underwent mass training, in which they were given 12 consecutive trials in one
day as described above, for 4 consecutive days. Twenty-four hours after the last trial, a
probe trial was performed in which the platform was removed and mice were allowed to
swim freely for 60 s. Latency to original platform location and number of times the mouse
crossed the original platform location were recorded. Mice were then spaced trained, which
consisted of 4 trials per day for 6 consecutive days. Twenty-four hours after the 6th day of
training, a probe trial was conducted. The platform remained in the same location
throughout both of these tests. Following all testing, the visual version of the Morris water
maze was performed by placing a large painted brick on top of the platform. Latency to the
visible platform and swim speed were recorded for each mouse and compared across
groups.
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Elevated Plus Maze (EPM) – EPM testing was conducted according to a protocol by Walf
and Frye (163). Briefly, an EPM made of heavy white plastic and consisting of four arms
(two open without walls and two enclosed by black plastic walls) was placed in the
previously described Morris water maze tub in a brightly lit testing room. Each arm of the
maze was attached to a thick plastic pipe to elevate the maze about 76 cm above the
bottom of the drained tub. Two partitions hid the maze and tub from the rest of the testing
room, where mouse cages were temporarily kept for testing.
All mouse testing was conducted between 11am and 4pm of the same day and the
maze was thoroughly cleaned with 70% ethanol between each test. At the beginning of
each test, mice were individually taken from their home cages and placed at the junction of
the open and closed arms, facing towards an open arm and away from the experimenter.
Mice were then observed for five minutes via an overhead camera by a blinded
experimenter who was hidden behind the partition. Total time spent on open arms as well
as entries into open and closed arms were manually assessed. Exploration into an arm was
considered an entry when at least half the body of the mouse was on the arm. Data from
mice that jumped off the maze was removed from the study (n=5, 3 WT and 2 postnatal
treated KO mice).

Contextual Fear Conditioning – The fear conditioning test was modeled after a protocol
described by Frankland et al. (164) in which the context of conditioning rather than an
auditory cue is paired with a mild footshock as a method to assess learning and memory
abilities. In our setup, the shock cage (Coulbourn Instruments) had a yellow and blackstriped back wall and was scented with pineapple soap. The similarly-sized safe cage
featured a blank white concave back wall that limited the floor space to a semicircle and
was cleaned with ethanol. The floor of both cages contained a footshock grid. Cages were
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placed side-by-side inside an internally-lit sound-proof box, though only one cage was used
at any given time. Mice were individually taken from their home cages in a separate room
and transported in a clean empty cage before each test. Each mouse was initially given 10
minutes to explore each cage, with no shock in either cage. The following day, mice were
trained for 3 minutes in each cage, during which a 0.75 mA, 2s-long shock was given in the
shock cage after 2 minutes and no shock was given in the safe cage. This experiment was
repeated the next day and continued for 3 more days using the same setup. Freezing
behavior was monitored in 2 s intervals throughout the 3 minutes in both cages by a blinded
observer, though only data from the first 2 minutes (pre-shock time) was used. Mice were
allowed a minimum of 3.5 hours between time in the shock cage and the safe cage
(morning then afternoon, or vice versa) and groups were counterbalanced across cage
testing order.

Object Recognition – Object recognition testing was carried out in two individual trials,
modified from a protocol by Bevins and Besheer (165). Briefly, mice were kept in their home
cages in the dark testing room until testing began. Mice were then individually removed
from their home cages and allowed to habituate for 10 minutes in an empty, approximately
15” x 15” x 18” (l x w x h) plastic-lined wooden box illuminated by a red light lamp.
Differences in trials only began 24 hours after initial habituation in the empty box. In the
long-term memory trial, mice were placed in the same box for 3 minutes with two identical
sample objects (plastic hamburger buns) that were secured in two adjacent corners of the
box with Velcro. Twenty-four hours later, one sample object was removed and replaced
with a novel object (brass weight), which the mouse was allowed to explore for 3 minutes.
In the short-term memory trial, mice were allowed to habituate with the two sample objects
(golf balls) for 10 minutes. One hour later, one sample object was replaced with a novel
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object (rubber stopper) and the mouse was allowed to explore for 3 minutes. In both trials,
all object interactions were filmed and the placement of the sample and novel object was
randomized between mice. All objects and the box were cleaned with 70% ethanol between
trials. Scoring of total time with each object was initially conducted by one blinded observer
and confirmed by a second blinded observer (Pearson’s r = 0.98).

Results
Combined pre+postnatal rapamycin treatment impairs long-term spatial memory
By comparing cognitive function of the Tsc2flox/ko; hGFAP-Cre pre+post rapamycin
treatment cohort to the postnatally treated cohort, we sought to determine whether the
greater histological rescue we observed in the former group translated to greater functional
rescue. As the most striking degree of histological improvement was found in the
hippocampus, we chose to focus on learning and memory tests that were hippocampusdependent. We began with the hidden-platform version of the Morris Water Maze (MWM),
in which the mouse uses spatial cues (Fig 5.1A) to locate a submerged platform in a tub of
opaque water (Fig 5.1B). The mice were initially placed through the more sensitive MWM
test of mass training (see Methods & Materials) for 4 consecutive days (Fig 5.1C).
However, mutant mice from both cohorts exhibited seizures and signs of exhaustion
throughout the tests (as demonstrated by minimal cleaning behavior when placed back into
the heated cage, labored breathing, and a hunched posture). As mutants from both groups
found the platform in similar amounts of time by Day 4, we felt comfortable transitioning to a
less stressful version of the MWM, which involved spaced training.
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Fig 5.1. Combined pre+postnatal rapamycin treatment of Tsc2flox/ko; hGFAP-Cre mice
impairs spatial learning and memory. (A,B) Mice were trained in the Morris Water Maze,
in which mice use spatial cues (A) around a tub of opaque water to find a submerged
platform (B). (C) Post and pre+post rapamycin-treated mice were initially mass-trained over
four days, though exhaustion and seizures in the mutants resulted in limited learning, as
shown by the average time to find the platform by day 4 compared to controls. (D) Pre+post
mutants took longer to find the platform compared to control and post mutants in the lessstressful spaced training task. Meanwhile the post mutants performed similarly to both post
and pre+post treated controls. (E, F) 24 hours after day 6 of spaced training, the platform
was removed and latency to find the platform location (E) and number of times the platform
location was crossed was recorded (F). Pre+post mutants look significantly longer to find
the platform and crossed it fewer times compared to control cohorts while post mutants
performed similarly to their treated controls. (G) These results were not due to differences
in swimming speed between groups, as measured using a visible platform.
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In spaced training, mice were trained over the course of 6 days and the average time
taken to find the platform, unmoved from mass training, was recorded per day (Fig 5.1D).
No seizures or signs of exhaustion were observed during this test. Interestingly, though
both pre+post and post rap mutants displayed similar latencies at the end of mass training,
pre+post mutants took significantly longer to find the platform on Day 1 of spaced training
compared to postnatally treated mutants. Though the average latency of pre+post mutants
slightly decreased per day, their final time on Day 6 was still notably longer than that of the
other cohorts. Meanwhile, the postnatally treated mutants consistently found the platform in
a similar amount of time as the control groups. Twenty-four hours after their last trial on Day
6, we performed a probe trial in which the platform was removed. Pre+post mutants took
significantly longer to locate the platform compared to the post rap mutants, who performed
similarly to the control (Fig 5.1E). Pre+post mutants also crossed the platform fewer times
on average than the post mutants (Fig 5.1F). These results were not due to differences in
motor ability, as swim speeds were similar among all groups (Fig 5.1G) and prior rotarod
testing showed no significant difference in latency to fall (data not shown). A visible-platform
version of the MWM confirmed that discrepancies were also not due to visual impairment,
as all mice were able to locate the platform in similar amounts of time in this case (data not
shown).

Combined pre+postnatal rapamycin treatment impairs contextual discrimination and
memory
To further investigate the apparent spatial learning and memory deficits of the
pre+postnatally treated cohort, we tested the mice for context discrimination and memory
abilities using contextual fear conditioning. This modified version of classical fear
conditioning is more hippocampal-dependent as it tests the ability of the mice to
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Fig 5.2. Combined pre+postnatal rapamycin treatment of Tsc2flox/ko; hGFAP-Cre mice
impairs contextual learning and memory. (A) Mice were tested for contextual memory,
where the time spent freezing in a shock cage versus safe cage is measured. The two
cages were located in a soundproof, darkened box as shown, with subtle differences
including background, shape, and smells differentiating the two cages. One cage (shown on
left) was always paired with the shock. (B-E) Over the course of 4 days, mice were
measured for time spent freezing in either cage prior to shock. By Day 4, control mice (B)
and postnatally treated mutants (C) froze longer in the shock cage versus safe cage,
whereas pre+post mutants froze for similar amounts of time in both cages (D). Results from
Day 4 are shown in bar graph in (E). (F) To demonstrate that freezing was not due to mere
anxiety about a new environment, freezing behavior was measured in the shock cage and a
completely novel context (cage in brightly lit room). All mice were able to distinguish
between the two contexts. Post-treated control (n=12), post-treated mutant (n=8), pre+post
treated mutant (n=9).
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discriminate between two slightly similar contexts, one of which is paired with a shock and
the other which is not (Fig 5.2A). Ability to discriminate is measured in percentage of time
spent freezing in the shock cage versus the safe cage. Over the course of 4 days, time
spent freezing in both cages was recorded (Fig 5.2B-D). By the fourth trial, postnatally
treated mutant and control mice froze significantly longer in the shock cage than the safe
cage, indicating they had learned to discriminate between contexts, whereas the freezing
time of the pre+post treated mutant did not differ between either cage (Fig 5.2E). To
determine whether mice were indeed remembering the shock and were not freezing due to
anxiety from being moved or touched, we measured freezing behavior of the mice first in
the shock cage and then in a novel, completely distinct cage. Both post and pre+post
mutants were able to discriminate between these contexts (Fig 5.2F), indicating our findings
were due to impaired contextual discrimination and memory in the pre+postnatally treated
mutant.

Rapamycin-treated Tsc2flox/ko; hGFAP-Cre mice display reduced anxiety-like behavior
Though the MWM and contextual fear conditioning are solid and informative tests to
assess hippocampal functions of learning and memory (166, 167), both tests involve a large
degree of stress. Results from other behavioral tests may hence be affected if certain
subjects are more susceptible to stress or anxiety than others. We therefore sought to
validate the last finding from our fear conditioning assay using another well-established test
for anxiety, the elevated plus maze (EPM, see Methods). Often used to measure the antianxiety effects of new pharmacological agents, increased time or entrances on the open
arms of the EPM are interpreted as indicators of alleviated anxiety (163). Post and pre+post
mutant mice entered both the enclosed and open arms more often than the control mice
(Fig 5.3A), indicating higher levels of activity. Interestingly, though they did not preferentially
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Fig 5.3. Rapamycin-treated Tsc2flox/ko; hGFAP-Cre mice display anti-anxiety behavior.
(A) Mice were tested for anxiety using the elevated plus maze, in which increased time or
entrances on open arms demonstrate anti-anxiety. Both post and pre+post mutants entered
the enclosed and open arms more frequently than controls, indicating higher levels of
activity. (B) Though mutants did not preferentially enter the open arms compared to
controls, they did spend more time on the open arms.
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enter the open arm over the closed arm, they did spend significantly more time on the open
arms than the control (Fig 5.3B). This finding suggests that the mutants of both treatment
groups display less anxiety than their littermate controls.

Short-term memory is intact in all rapamycin-treated cohorts
To better understand why long-term learning and memory seemed to be disrupted in
the pre+post mutant mice, we tested all groups for short-term memory using the object
recognition test. This test makes use of the observation that mice preferentially interact
with a previously unexplored object. Mice are hence exposed to two identical objects in
phase one before one object is replaced with a novel object in phase two. Interaction time
with each object is recorded. To test short-term memory, we allowed a one-hour interval
between the two phases. Mutant and control
mice from both treatment groups all interacted for a greater length of time with the novel
object, demonstrating that short-term memory was not impaired in any group.

Discussion
In this study, we examined the functional effects of post and pre+post rapamycin
treatment by testing the learning and memory abilities of treated Tsc2flox/ko; hGFAP-Cre and
control mice. We hypothesized that pre+post treated mutant animals would behave more
like control animals since histologic rescue was most similar to control brains. Surprisingly,
mutant mice treated pre+postnatally were impaired in spatial and contextual long-term
learning and memory compared to postnatally treated mutant and control animals as
demonstrated using the MWM and contextual fear conditioning tasks. Postnatally treated
mutants, on the other hand, performed as well as post and pre+post treated controls. Both
105

Fig 5.4. Short-term memory is intact in all rapamycin-treated cohorts. (A) The lowstress object recognition task was used to assess short-term memory. In this task, mice are
habituated in a box then allowed to interact for 10 minutes with two identical objects (left).
One hour later, one original object is replaced with a novel object and interaction with both
objects is timed for 3 minutes. (B) All mice preferentially interacted with the novel object
than the original, demonstrating intact short-term memory in all groups.
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mutant groups also demonstrated reduced anxiety-like behavior in the elevated plus maze.
Meanwhile, the short-term memory of all groups appeared intact as demonstrated by the
object recognition task.
We originally hypothesized that the greater degree of histological rescue found in
the pre+post mutants would translate to improved cognitive function compared to the post
rap mutants, though this was demonstrated to be incorrect. Though post and pre+post
mutants exhibited similar degrees of rescue of defects in cortical thickness, cell size,
hypomyelination, and astrogliosis, pre+post mutants showed significantly improved
lamination, an important factor in proper cognitive function. Despite their improved
lamination, however, the pre+post mutants displayed significantly impaired learning and
memory compared to post rap mutants. These results may be explained by considering the
fact that while appropriate migration of cortical and hippocampal neurons is indeed critical
to brain function (136), many other factors are involved in long term memory and learning,
such as neurotransmitter homeostasis as well as dendrite and synapse formation and
function (168). Studies in the astrocyte-specific Tsc1 CKO mouse (93), for example,
revealed abnormal glutamate homeostasis and subsequent impairments in MWM and fear
conditioning results. Interestingly, the untreated Tsc2flox/ko; hGFAP-Cre mouse has been
found via Sholl analysis to have significantly increased dendritic branching, while dendritic
spines appear round and mushroom-like (data not shown). Though our histologic analysis
demonstrated rescue of some defects, we did not assess the impact of rapamycin on the
increased dendritic arborization or many other factors that are important for proper brain
function such as axon formation, neurotransmitter production and release, and
neurotransmitter receptor density. Investigation of how prenatal versus postnatal rapamycin
impacts these factors will be essential in helping us better understand the role of the
mTORC1 pathway in cognitive function.
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We consistently found that postnatally-treated mutant mice performed similarly to
treated controls. This result suggests that postnatal treatment with rapamycin, when
administered from birth, is able to restore learning and memory abilities in mutant mice. Our
finding is similar to that shown by Ehninger et al. (2008), who demonstrated that rapamycin
treatment was able to reverse spatial learning and contextual discrimination defects in 3-6
month old Tsc2+/- mice compared to vehicle controls, using the MWM and same context
discrimination task we chose. However, as our experiments did not include a naïve or
vehicle-treated control group, we cannot conclusively determine whether postnatal
treatment in the Tsc2flox/ko; hGFAP-Cre mice rescued learning and memory abilities. As
rapamycin has been shown to impair learning and memory in vivo (161), treated control
mice might therefore also be impaired in their cognitive functions. We are currently testing
untreated control mice to resolve this concern, as it is critical to understand whether
rapamycin has detrimental effects on control animals. If impairment at this low dosage is
minimal, then our results would indicate that postnatal treatment from birth can not only
restore health, increase lifespan, and alleviate a number of histologic brain defects, but
improve cognitive function as well. This would pave the way for exciting translational trials
in neonates affected with TSC.
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Chapter Six:
Significance and Future Directions
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Introduction
Nearly a century and a half after Bourneville’s initial account of TSC, much
regarding its genetic etiology and relevant pathways has been discovered thanks to the
efforts of generations of physicians, researchers, and patients. However, significant gaps
still exist in our understanding of the pathophysiology of the disease, particularly in regard
to the debilitating neurological manifestations. In this dissertation, we sought to address
some of these unknowns through the creation, characterization, and rapamycin treatment of
a novel brain-specific mouse model of TSC, Tsc2flox/ko;hGFAP-Cre. We hypothesized that
deletion of Tsc2 in radial glial cells would result in a mouse that recapitulated many aspects
of TSC neuropathology. Using this mouse, we proposed to test the extent of mTORC1
involvement in TSC brain pathology formation by inhibiting mTORC1 with the macrolide
rapamycin, while also demonstrating the therapeutic potential of this drug as a TSC
treatment.
As described in previous chapters, the results of our study have yielded a number of
novel findings. First, deletion of Tsc2 in radial glial cells does indeed give rise to many TSClike brain defects, indicating that these neuroglial progenitor cells may play a large role in
TSC neuropathology. Second, loss of heterozygosity, as modeled in our mouse, leads to
TSC-like brain pathology, lending support to the two-hit hypothesis for brain lesion
formation in this disease. Third, inhibition of mTORC1 over-activity with rapamycin
alleviates many TSC defects, demonstrating the high degree of involvement the mTORC1
pathway has in TSC pathology formation. Fourth, a low dosage of rapamycin is sufficient to
effect histologic rescue in our mice, suggesting that the extremely high dosages used in
other mouse studies may be unnecessary and/or lead to undesired side effects for
translational studies. Fifth, combined prenatal and postnatal treatment with rapamycin
resulted in the greatest histologic rescue of defects in neuronal migration compared to
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individual prenatal or postnatal treatment, indicating that proper mTORC1 activity is
required for correct migration throughout all stages of neurodevelopment. Sixth, prenatal
rapamycin treatment is detrimental to learning and memory, suggesting that inhibition of
mTORC1 activity may cause side effects during early development. Lastly, postnatal
rapamycin administration in our model results in learning and memory abilities similar to
those of treated control mice, a result that may support the novel treatment modality of
rapamycin treatment in neonates with TSC.
The work described in this thesis has provided an excellent tool for the study of TSC
in the brain and greatly enhanced understanding of the defects involved in TSC brain
pathology. In addition, it has indicated a significant role of mTORC1 in TSC neuropathology
formation, though much remains unknown regarding the downstream effectors and
mechanisms by which this kinase induces lesion formation. The Tsc2flox/ko;hGFAP-Cre
mouse model will be extremely useful in future studies that involve elucidating or verifying
the mechanisms underlying formation of these defects. Below, I will discuss potential
mechanisms that lead to two of the most prominent yet poorly understood defects found in
TSC brain pathology, neuronal migration and myelination, and how these mechanisms
might explain our findings in the Tsc2flox/ko;hGFAP-Cre mouse. In addition, I will propose
future work to investigate these mechanisms and enhance our understanding of TSC
neuropathology formation.

mTOR and Neuronal Migration
As previously discussed, cellular migration is a highly regulated process that is
essential to proper brain function. As described in the discussion section of Chapter 3, the
defects in migration in TSC brain lesions are so severe that the disease may be considered
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a neuronal migration disorder (16). We also found significant defects in neuronal migration
in the cortex and hippocampus in the untreated Tsc2flox/ko;hGFAP-Cre mouse, as indicated
by poorly defined cortical layers, the presence of cells stained with an upper-layer marker in
the lower layers of the cortex, and ring heterotopias and an ectopic layer of cells above the
pyramidal layer of the hippocampus. Prenatal rapamycin treatment resulted in alleviated
cortical migration defects, though hippocampal abnormalities were not significantly affected,
while our analysis demonstrated that postnatal rapamycin treatment had no significant
effect on migration. A combination of prenatal and postnatal treatment, however, resulted in
significant rescue of both cortical and hippocampal migration defects. These results indicate
the need for proper mTORC1 function during both prenatal and postnatal
neurodevelopment for correct neuronal migration.

A. Migration and the Cell Cycle
A1. Cell cycle progression and cell size
Several studies have implicated the impact of mTORC1 on cell cycle progression as
a major mechanism by which the kinase is involved in migration. Laminar organization in
the cortex requires precise coordination between the timing of cell cycle exit of progenitor
cells and the determination of their laminar fate, which occurs during the S phase of the last
cell division (169). Fingar et al. (170, 171) established in vitro that S6K1 and 4E-BP1, wellestablished downstream effectors of mTORC1, were responsible for mTORC1’s control of
G1-phase progression. They hypothesized that their results might indicate a model in which
cell growth and cell cycle are closely coupled, such that mTORC1 primarily drives cell
growth via macromolecular biosynthesis, with progression of the cell cycle being a
secondary consequence. However, they also noted a rapamycin-insensitive and therefore
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mTORC1-independent aspect of G1-phase progression and suggested a possible role for
the mammalian orthologue of a yeast protein, TORC2, known at the time to mediate both
rapamycin-sensitive and -insensitive signals. Later studies confirmed the presence of
mTORC2 (96), a rapamycin-insensitive second kinase complex of mTOR, which is
activated by the TSC complex (95) and activates Akt via phosphorylation (172, 173).
Though FKBP12-rapamycin cannot bind directly to mTORC2, prolonged presence of
rapamycin allows it to bind to free mTOR and thereby inhibit mTORC2 assembly and
consequently Akt activity (100). Rosner et al. (174) later demonstrated in primary nontransformed, non-immortalized human fibroblasts that mTORC1 was able to control the cell
cycle via the aforementioned downstream effectors independently of mTORC2 activity.
However, mTORC2 was also able to regulate cell size and the cell cycle through its
activation of mTORC1 via Akt/Tsc2/Rheb. These studies indicate the critical role of
mTORC1 and mTORC2 in controlling cell size as well as cell cycle progression, which is
closely tied to migration.

A2. Cell cycle progression and cyclin-dependent kinase inhibitor p27Kip1
Another method of regulation of the cell cycle by the mTOR complexes,
independent of S6K1 and 4E-BP1 translational activity, was recently proposed in which
mTOR promotes the phosphorylation and therefore targeted degradation of p27Kip1, a
Cip/Kip cyclin-dependent kinase inhibitor (CKI) highly involved in brain development (175).
p27Kip1 promotes cell cycle exit at the G1 restriction point by blocking the catalytic activity of
cyclin E/A and cdk2 (cyclin dependent kinase 2) (176), inhibiting phosphorylation of pRb
(retinoblastoma protein) and halting transcription of genes required for transition from G1 to
S phase (Koff, Polyak, 1995, Cell Cycle Res). p27Kip1 is therefore particularly involved in

113

determining the length of the cell cycle and the probability of cell cycle exit (Lukaszewicz,
Savatier, 2005, Neuron), and therefore the birth date of projection neurons. Increased
mTOR activity hence enhances cell cycle progression through degradation of p27Kip1 (177).
Accordingly, p27Kip1 knockout mice demonstrate increased cell proliferation and enlarged
brains, particularly as a result of thicker upper cortical layers at the expense of lower layers
(178). This finding of enlarged brains and decreased lower layer neuron population is
similarly found in the Tsc2flox/ko;hGFAP-Cre mouse model, in which overexpression of
mTOR may be leading to increased degradation of p27Kip1. These findings suggest that
p27Kip1 may play a role in the formation of TSC brain pathology.

A3. Future examination of the cell cycle
With the similarities between the Tsc2flox/ko;hGFAP-Cre mouse model and p27Kip1
knockout mice, it is important to investigate the activity of p27Kip1 as well as the contributions
of the cell cycle to the phenotype found in our model. Direct visualization of phosphorylated
and unphosphorylated p27Kip1 expression via immunohistochemical staining or
immunoblotting may be easily conducted during mid-neurogenesis timepoints, such as
E13.5 and E16.5. As mTOR activity is highly increased in the mouse model, p27Kip1
presence should be decreased, and therefore increase of G1 to S cell cycle progression
should be noted. Unchecked protein synthesis via upregulated mTORC1 activity may also
disrupt the cell cycle and contribute to the observed migration defects. Basic analysis of cell
cycle progression should therefore be conducted, and may be quickly performed using
immunohistochemical labeling and quantitation of cells with cell-cycle markers such as antipH3, a marker of cells undergoing mitosis, which might be conducted at E12.5, E14.5,
E16.5, and E18.5 to compare differences in M phase activity between the control and
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mutant mice. Comparison of number of cells exiting the cell cycle may also be analyzed
using co-labeling of BrdU, an S-phase marker, and Ki67, a cell cycle marker. This
experiment involves injecting pregnant dams with BrdU, waiting 24 hours for a full cell cycle
then co-labeling with anti-BrdU and anti-Ki67 antibodies, and quantitating cells that are
BrdU+ but Ki67-. This experiment might also be conducted at a variety of embryonic
timepoints to investigate cell cycle progression and regulation in the mouse model. We
have currently initiated analysis of expression arrays from cortical samples taken at E14.5,
E16.5, and P10. Investigation of these samples and additional proteomic array analysis at
these timepoints will further establish presence of relevant cell cycle components.
Repetition of these studies using Tsc2flox/ko;hGFAP-Cre mice undergoing concurrent
rapamycin treatment, in which we see improvement of migration defects, might determine
whether cell cycle components, and in particular p27Kip1, play a significant role in formation
of these defects.

B. Migration and the Rho Family Small GTPases
B1.The Rho family small GTPases
The Rho family of small GTPases, most notably RhoA, Rac1, and Cdc42, are crucial
regulators of cellular migration that cycle between an inactive GDP-bound form and an
active GTP-bound form. RhoA advances the formation of actin stress fibers and focal
adhesions (Ridley, 1992, Cell; Amano, 1997, Science) while controlling actin-myosin
contractility, which is important for translocation of the cell body and retraction of the rear of
the cell (179). Rac1 promotes formation and extension of lamellipodia, whereas Cdc42
stimulates formation of filopodia (180). Proper cellular migration particularly requires a
balanced polarity between Rac1 and RhoA, with higher Rac1 activity present at the leading
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edge of the cell and higher RhoA activity at the rear of the cell (Woods, 2010, Cell Cycle).
Disruption of this balance disrupts migration and impacts other morphological events such
as growth-cone motility and axon guidance in the cell (181) .

B2. p27Kip1 and RhoA
In a function distinct from its regulation of the cell cycle, p27Kip1 has been shown to play
a more direct role in migration by modulating RhoA activation. p27Kip1 was found by Besson
et al (182) to inhibit RhoA via direct binding to prevent its interaction with its guaninenucleotide exchange factors (GEFs), which exchange GDP for GTP and thereby activate
RhoA (183)(Schmidt &Hall, 2002, Genes Dev). Mouse embryonic fibroblasts (MEFs)
derived from p27Kip1 knockout mice had impaired mobility, increased numbers of stress
fibers, and increased numbers of focal adhesions (182), likely due to the imbalance
between RhoA and Rac1. In a separate experiment, prolonged but not acute treatment with
rapamycin in vitro caused an increase in p27Kip1 presence and also impaired RhoA activity
and cell migration, results of which could be mimicked by mTORC2 siRNA inhibition,
implicating the specific role of mTORC2 in negatively regulating p27Kip1 (175) and
underlining the delicateness of RhoA/Rac1 balance. As the loss of the TSC complex has
been shown to impair mTORC2 kinase activity in vitro (95), loss of Tsc2 in the
Tsc2flox/ko;hGFAP-Cre mouse likely also results in impaired mTORC2 activity. According to
the results discussed above, this would lead to reduced degradation of p27Kip1, greater
inhibition of RhoA, and consequent decrease in cell motility, which may explain the
migration defects found in the model. However, prolonged treatment with rapamycin at our
dosage alleviated these migration defects rather than exacerbated them, suggesting that
alternate mechanisms in regulation of migration need to be explored.
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B3. S6K1, 4E-BP1, and the Rho family small GTPases
The involvement of mTOR in regulating RhoA, Rac1, and Cdc42 was further confirmed
in a recent study by Liu et al. (184), in which rapamycin treatment was found to inhibit
protein synthesis and the activity of the three GTPases in vitro. While this study makes no
mention of p27Kip1, it instead implicates a different set of regulators of RhoA, Rac1, and
Cdc42 - the downstream effectors of mTORC1, S6K1 and 4E-BP1. By disrupting mTORC1
or mTORC2 by down-regulating raptor or rictor, respectively, the authors were able to
conclude that mTORC1 was involved in inhibiting the protein synthesis of the three
GTPases, whereas mTORC2 mainly inhibited their activity, as measured by decreased
GTP-bound forms of the GTPases. Prolonged rapamycin treatment, however, mainly
suppressed RhoA, Rac1, and Cdc42 activity and therefore cell motility by inhibiting the
protein expression of the small GTPases. Meanwhile, rapamycin inhibition could be
overcome by overexpression of RhoA but not the other proteins, suggesting that rapamycin
inhibits cell motility at least in part through attenuation of RhoA protein expression. These
results indicate a larger role of mTORC1 in migration than the aforementioned studies
implied. It is therefore possible that overactivation of mTORC1 in the Tsc2flox/ko;hGFAP-Cre
mouse and the resulting migration defect is attenuated through rapamycin treatment, which
results in restored balance to RhoA levels and subsequent appropriate migration.

B5. Future examination of the Rho family small GTPases
The relationship between the mTOR complexes and RhoA, Rac1, and Cdc42 as
described above suggest that the Rho family of small GTPases may play an important role
in the migration defects found in TSC pathology. Though these in vitro studies show that
prolonged rapamycin inhibits migration through these proteins at least in some part, it is
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unclear how the small GTPases are impacted by treatment following the removal of Tsc2,
particularly in an in vivo system. Characterization of the activity of RhoA, Rac1, and Cdc42
as well as the phosphorylation status of the two mTOR complexes in the Tsc2flox/ko;hGFAPCre mouse will therefore be very useful in investigating this question. Phosphorylation
status and protein presence may be measured using immunoblot analysis of embryo cortex
and hippocampal lysates throughout corticogenesis, for example at E13.5, E15.5, E17.5,
and P0. Activity of the small GTPases may be more specifically measured using affinity
binding assays to pull down GTP-bound RhoA, Rac1, and Cdc42 before immunoblot
analysis. Investigation of these and other migration-linked effectors via expression and
proteomic arrays may further establish the roles of these and other proteins in the formation
of TSC defects. For example, analysis of E16.5 cortical samples by expression array in our
lab has demonstrated a significant increase in expression of Pak1 in the Tsc2flox/ko;hGFAPCre mouse compared to a littermate control. As Pak1, a downstream effector of Rac1 and
Cdc42, is an important regulator of neuronal polarity, morphology, migration, and synaptic
function (Nikolic 2008 Mol Neurobiol), investigation of why this protein is so highly
upregulated following Tsc2 deletion will provide direct insight into TSC pathology formation.

mTOR and Myelination
A. Myelination and Migration
In addition to neuronal migration, the Tsc2flox/ko;hGFAP-Cre mouse is also
characterized by defective myelination. Developmental studies, as described in Chapter 3,
indicated that the hypomyelination observed in the adult was due to aberrant progression of
myelin into the lower cortical layers, rather than as a result of demyelination. Though myelin
presence, as visualized by immunohistochemistry using MBP as a marker, appears slightly
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patchy in the corpus callosum, actual formation of myelin does not seem to be severely
affected. Our investigation of mature oligodendrocytes using antibodies against CC1
demonstrated in the Tsc2flox/ko;hGFAP-Cre mouse an increased number of oligodendrocytes
in which mTORC1 was also upregulated. Whether increase in mTORC1 activity or increase
in cell number affects the ability of oligodendrocytes to myelinate remains to be studied.
The neuron-specific Tsc1 CKO mouse, however, demonstrates similar myelination defects
as our model, without evidence of increase in or aberrant distribution of oligodendrocytes
(77), indicating that these particular characteristics may play a lesser role in the
hypomyelination phenotype. Before alternate hypotheses may be studied, however, we
must first establish that oligodendrocytes are correctly distributed throughout the cortex in
the Tsc2flox/ko;hGFAP-Cre mouse. Oligodendrocyte precursor cells (OPCs) move using
saltatory migration (185), in which the leading edge of the cell orients towards the pial
surface with alternating stationary and fast-moving phases, including dramatic shape
changes (186). This method of movement resembles formation of axonal growth cones, a
process which incorporate signals from the previously mentioned RhoA and its related
effectors (187). Given that RhoA signaling is likely highly altered in the Tsc2flox/ko;hGFAPCre mouse, OPC migration to a position appropriate for myelination may also be
compromised. Use of immunohistochemical markers such as Olig2, MOG, and CC1 to
visualize and quantitate OPC and mature oligodendrocytes should be sufficient to establish
proper placement of these cells for myelination.

B. Myelination and Axonal Surface Molecules
As characterization of the neuron-specific Tsc1 CKO did not yield differences in
OPC distribution or number, the authors instead suggested that hypomyelination was seen
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as loss of Tsc1 in neurons might inhibit the induction of myelination (77). This hypothesis is
quite plausible, given that myelination of individual axons by oligodendrocytes may be
heavily regulated by extracellular ligands and secreted molecules present on the surface of
the axon itself (188). As support, Meikle et al (2007) cite high expression of the growthassociated protein GAP-43 in the P21 mouse model. GAP-43 has a distinct inverse
relationship with myelin (189) and is usually expressed during axonal outgrowth before P7
(190), indicating that neurons may be more responsible than oligodendrocytes in causing
the hypomyelination defect observed. Initial effort might therefore focus on investigating
aberrant neuronal signaling to oligodendrocytes in the Tsc2flox/ko;hGFAP-Cre mouse. A
number of well-characterized axonally expressed ligands may be studied for this purpose,
such as Jagged, PSA-NCAM, and LINGO-1, all of which inhibit the differentiation of OPCs
or myelination (191-193).

B. Myelination and Neuronal Activity
Deletion of Tsc2 and subsequent mTORC1 activation in the Tsc2flox/ko;hGFAP-Cre
mouse may also alter electrical activity of the axons, which in turn may influence
myelination (194, 195). Aberrant neuronal activity may alter expression of the previously
mentioned surface ligands. Unregulated release of neurotransmitters such as adenosine by
active axons might also inhibit or disrupt OPC differentiation and subsequent myelination
(196). Investigation of neurotransmitters in vivo may be conducted via microdialysis or
direct electrochemical methods, while detection of individual neuronal activity can be
achieved via patch clamping of cultured brain slices.
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Model Summary
Though TSC neuropathology is characterized by a number of defects, aberrant
neuronal migration and hypomyelination are two of the most cardinal and poorly understood
traits. As these characteristics are also well-recapitulated in the Tsc2flox/ko;hGFAP-Cre
mouse model, I have focused on them in this discussion to better guide future investigation
into the formation of these defects. Neuronal migration may be controlled by a number of
factors, most prominently release of the cell from the cell cycle and physical ability of the
cell to move. The important roles of p27Kip1 and mTORC1’s downstream effectors S6K1 and
4E-BP1 in controlling the cell cycle as well as Rho family small GTPases have therefore
been discussed, with future study emphasizing the relative levels of these proteins at
different developmental timepoints. Myelination may be highly affected by inhibited OPC
movement or altered neuronal induction, whether by surface molecule or neurotransmitter
signaling. Investigation of OPC/oligodendrocyte positioning and electrical/biochemical
signaling to determine what is causing the aberrant myelin progression is therefore
relevant. The results of these proposed studies will provide much-needed insight into the
neuronal migration and hypomyelination defects seen in TSC pathology. I will now discuss
additional future studies which may also enhance our understanding of TSC
neuropathology formation.

Additional Future Studies
A. Creation of a tuber-based mouse model
One of the main criticisms of our model, as well as that of the Eker rat and TSC1 CKO
models, has been the absence of focal tubers, a defining characteristic of TSC
neuropathology. In a TSC Investigator’s Meeting workshop, participants felt that:
121

The relevance of all of these results [from animal models]
to human TSC remains to be established( [participants]
remained cautious of direct correlation to human TSC.
Despite the variety of neuropathology in these models,
none expressed typical cortical tubers (197).

In response to this critique, Wong (198) correctly pointed out that a number of findings
derived from “tuberfree” animal models have already impacted understanding of human
TSC. He cites as examples the discovery of the role of the TSC complex in the mTORC1
pathway, originally found in Drosophila (52, 199) and now the basis for rapamycin
treatments, as well as abnormalities in astrocyte glutamate transporters, found in the
astrocyte-specific TSC1 CKO (200) and now verified in human TSC tissue (201). He
concludes that while caution is always appropriate when interpreting animal data, data from
these models have already been found to have direct clinical applications to TSC.
While study of models that do not display focal tubers has indeed been extremely
informative, it is also important to note that though we do not see focal tubers per se, many
of the characteristics found throughout the Tsc2 flox/ko; hGFAP-Cre brain model those of
tubers. It is thought that tubers form from a single progenitor (202). By deleting Tsc2 in all
radial glial progenitor cells, we have recapitulated much of the disease and in many
respects created a “holotuber.” Some aspects of TSC, such as seizures and cognitive
disabilities, may admittedly be much more severe in this mouse due to the presence of
tuber-like defects throughout the entire brain rather than in an isolated area surrounded by
normal tissue. Other characteristic defects such as migration problems or giant cells,
however, are likely similar to those found in isolated lesions.
Now that we have defined and examined these characteristics in our mouse model,
future experiments may satisfy critics of our “tuberless” model relatively easily by deleting
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Tsc2 in only a few radial glial cells. This may be achieved most efficiently using an hGFAPCre retrovirus, which if delivered at low titer and directly to the ventricles of Tsc2flox/ko
embryos, may result in focal deletion of Tsc2 in dividing radial glial cells. This experiment
would validate whether tubers can originate from radial glial cells, as well as elucidate the
contributions of a haploinsufficient environment to the localized tuber by comparing its
characteristics with those of our original Tsc2 flox/ko; hGFAP-Cre mouse. Though inherent
differences between the mouse and human brain, such as the lissencephalic nature of the
mouse brain, may prevent actual tuber formation, results of this experiment would be very
informative and perhaps more appealing to human-centric investigators.

B. Further investigation of differentiation and proliferation defects
Though the Tsc2flox/ko;hGFAP-Cre mouse does recapitulate the majority of
characteristics found in TSC brain lesions, we see little evidence of the prominent defects of
abnormal differentiation and proliferation. While one explanation might be that radial glial
cells (RGCs) only partially contribute to the TSC brain phenotype and therefore these
particular defects are not present in our model, several findings indicate otherwise. Ring
heterotopias in the hippocampus reveal cells that do not stain for post-mitotic neuronal or
glial markers, suggestive of a problem with differentiation into one or the other cell line.
Meanwhile, embryonic analysis demonstrated aberrant populations of neural progenitor
pools, indicating either aberrant differentiation into post-mitotic neurons or basal progenitor
cells (BPCs), or possibly a proliferation defect in one progenitor pool. Future work might
focus on characterizing these defects more thoroughly, prenatally as well as postnatally, in
these mice.
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For example, though we did not find aberrant proliferation in the mutant embryos using
our methods as described in Chapter 3, proliferation is often the most common explanation
for a greater number of cells. Other experiments must therefore be conducted to validate
our initial findings that aberrant proliferation of RGCs and BPCs did not occur. While cell
counts at a certain timepoint are useful, they do not distinguish between (1) lack of a
proliferation defect, which we originally concluded, (2) a proliferative event followed closely
by cell death, and (3) a proliferative event immediately followed by differentiation into other
cell types, such as post-mitotic neurons or BPCs, which would not stain for the original cell
marker and therefore not be counted. As altered progenitor pools are found by E14.5 and
Tsc2 deletion only occurs two days prior, evidence of cell death should be easy to detect
around E13.5 should it exist. Immunohistochemistry with antibodies against a cell death
marker such as CC3 or TUNEL staining would therefore be useful. Though we
investigated proliferation using BrdU, we were unable to distinguish between RGCs and
BPCs undergoing S phase based on location alone, due to the interkinetic nuclear
oscillations of RGCs during synthesis towards the subventricular zone where BPCs reside
(139). By double-labeling with the robust BPC marker Tbr2 and BrdU, we will be able to
determine whether more RGCs are undergoing S phase in the mutant compared to control.
To identify whether cells are leaving the cell cycle to become post-mitotic neurons, we may
inject BrdU, wait 24 hours for completion of a cell cycle, and double label with BrdU and
Ki67, a general marker of mitosis. An increase of cells that are BrdU+/Ki67- in the mutant
would suggest that cells were undergoing synthesis but then leaving the cell cycle.
Together, these three experiments would clarify whether proliferation plays a role in the
altered progenitor pool defect rather, or in addition to, differentiation.
Postnatal analysis must also be conducted more thoroughly to establish whether these
two defects are present in our mouse model. Our experiments thus far have used markers
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that identify post-mitotic neurons or glia for our cell counts, rather than markers that
investigate immature cells. Crino et al (203) showed that tubers contained cells stained with
nestin, an embryonic intermediate filament protein, PCNA (proliferating cell nuclear
antigen), and Ki-67. These markers are expressed during embryonic development but not
by mature neurons after migration, demonstrating that many cells in tubers are
developmentally retarded. Repeating this experiment in our mutant mouse at P0, P5, P10,
and P15 might therefore reveal defects in proliferation and differentiation better than cell
counts alone.

C. Characterization of seizure phenotype
Epilepsy is one of the most common neurological manifestations of TSC, as well as one
of the most devastating (204). Nonfatal seizures have been routinely observed in both
TSC1 CKO mouse models throughout their lifespan (93, 94). Our mutant mice, however, do
not exhibit a clinical seizure phenotype until P23, when seizures consistently end in a fatal
tonic phase. It is unclear how the seizure phenotype in our mouse compares to those of the
other mouse models. This question is particularly interesting given that our mouse
demonstrates more severe histologic defects than either mouse. Investigation of the
underlying seizure phenotype of our mutant may therefore elucidate the importance of
certain TSC defects to seizure events.
Additionally, we have observed several nonfatal seizures in our mice following
rapamycin treatment. As rapamycin has been shown to alleviate seizures in both TSC1
CKO mice as well, it would be interesting to see what impact our lower dosage of
rapamycin might have on seizure activity. Measuring differences between seizure
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phenotype in our pre, post, and pre+post rapamycin treated cohorts would also be useful in
establishing which treatment might be more beneficial for this aspect.
The standard method of seizure assessment is via video-EEG recordings. In mice, this
requires surgical implantation of epidural screw electrodes and a monitoring setup, which
our lab is currently not equipped for. However, such an experiment would be particularly
useful for our mice, as this method would not only measure seizures but also provide a
background EEG. As we see low frequency of seizures in the treated mice, interictal EEG
activity would provide adequate data regarding the impact of different rapamycin treatments
on brain functioning, perhaps enough to determine whether prenatal treatment was more
beneficial for seizure management.
As our lab is currently best suited for histological study, however, characterization of
seizure activity via Timm staining may be more appropriate. The Timm stain allows
visualization of zinc deposits that accumulate along mossy fibers that are produced by hilar
cells of the hippocampus. While it is unclear whether mossy fiber sprouting is a cause or
effect of seizures (Koyama & Ikegaya 2004, Curr Neurovasc Res), Timm staining is
frequently used to assess the seizure phenotype. In fact, rapamycin has been shown to
decrease mossy fiber sprouting (Buckmaster 2009, J Neurosci). Though this data was not
coupled with EEG recordings, it provides support that Timm staining in our mice might
provide a more practical method of assessing variation between benefits of rapamycin
administered at different timepoints.

Conclusion
This dissertation describes the creation, characterization, and treatment of a novel,
Tsc2-based radial glial model of TSC brain pathology in the mouse, Tsc2flox/ko;hGFAP-Cre,
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which recapitulates many features of TSC neuropathology. Our studies with this mouse
have yielded a number of significant and novel findings. We have confirmed the radial glial
cell as a likely source of TSC brain pathology formation, gathered evidence to support LOH
as a mode of brain lesion formation, and established a significant role for mTOR in
regulating brain size, neuronal size and migration, myelination, astrogliosis, and learning
and memory. This work has provided an excellent tool for the study of TSC in the brain,
while characterization of this model has also greatly enhanced the understanding of the
defects involved in TSC neuropathology. Using this model, additional studies may also be
conducted to elucidate the currently poorly understood mechanisms by which TSC brain
pathology forms. Moreover, our investigations of rapamycin treatment of this mouse model
at different time points may establish precedent for novel treatment modalities in the clinic,
further establishing the high impact the Tsc2flox/ko;hGFAP-Cre mouse has and will continue
to have on increasing our understanding of TSC.
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